Deciphering ARAP3 Functions in Hematopoiesis and Hematopoietic Stem Cells by Song, Yiwen
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2015
Deciphering ARAP3 Functions in Hematopoiesis
and Hematopoietic Stem Cells
Yiwen Song
University of Pennsylvania, yiwen.song@gmail.com
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Developmental Biology Commons, and the Molecular Biology Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/1141
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Song, Yiwen, "Deciphering ARAP3 Functions in Hematopoiesis and Hematopoietic Stem Cells" (2015). Publicly Accessible Penn
Dissertations. 1141.
http://repository.upenn.edu/edissertations/1141
Deciphering ARAP3 Functions in Hematopoiesis and Hematopoietic
Stem Cells
Abstract
ARAP3 is a GTPase-activating protein that inactivates Arf6 and RhoA GTPases. ARAP3 deficiency in mice
causes a sprouting angiogenic defect resulting in embryonic lethality by E11. Mice with an ARAP3
R302,303A mutation (KI/KI) that prevents activation by PI3K have a similar angiogenic phenotype, although
rare animals survive to adulthood. Although ARAP3 was first discovered in porcine leukocytes, it remains
largely unstudied in hematopoiesis and hematopoietic stem cells (HSCs). In this thesis, we aim to elucidate
the potential cell-autonomous and non-cell-autonomous roles of ARAP3 in hematopoiesis and HSCs using
several conditional knockout (CKO) transgenic mouse models in addition to the KI/KI mutant mouse
model. Here, we report that HSCs from surviving adult KI/KI bone marrow (BM) are compromised in their
ability to self-renew and reconstitute recipient mice. To decipher the possible mechanisms of the KI/KI
mutation, we utilize our genetic CKO models to conditionally delete Arap3 in hematopoietic cells and in
several cell types within the HSC niche. Excision of Arap3 in hematopoietic cells using Vav-Cre does not alter
the ability of ARAP3-deficient HSCs to provide multi-lineage reconstitution and to undergo self-renewal,
suggesting ARAP3 does not play a cell-autonomous role in HSCs. Deletion of Arap3 in osteoblasts and
mesenchymal stromal cells using Prx1-Cre resulted in no discernable phenotypes in hematopoietic
development or HSC homeostasis in adult mice. However, reverse transplantation into Arap3;Prx1 CKO
mice resulted in an expanded phenotypic HSC compartment, suggesting ARAP3 plays a crucial role in the
BM niche to maintain and regulate HSC self-renewal. In contrast, deletion of Arap3 using VEC-Cre resulted
in embryonic lethality, yet HSCs from surviving adult mice were largely normal and reverse transplantation
into Arap3;VEC CKO mice revealed HSC frequencies and functions comparable to control mice. Taken
together, this thesis work suggests that despite a critical role for ARAP3 in embryonic vascular development,
its loss in endothelial cells minimally impacts HSCs in adult BM; however ARAP3 may play a pivotal role in
the mesenchymal and osteoblastic BM niche to regulate HSC functions.
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ABSTRACT 
DECIPHERING ARAP3 FUNCTIONS IN HEMATOPOIESIS AND 
HEMATOPOIETIC STEM CELLS 
Yiwen Song 
Wei Tong, Ph.D. 
 
ARAP3 is a GTPase-activating protein that inactivates Arf6 and RhoA GTPases. ARAP3 
deficiency in mice causes a sprouting angiogenic defect resulting in embryonic lethality 
by E11. Mice with an ARAP3 R302,303A mutation (KI/KI) that prevents activation by 
PI3K have a similar angiogenic phenotype, although rare animals survive to adulthood. 
Although ARAP3 was first discovered in porcine leukocytes, it remains largely unstudied 
in hematopoiesis and hematopoietic stem cells (HSCs). In this thesis, we aim to elucidate 
the potential cell-autonomous and non-cell-autonomous roles of ARAP3 in 
hematopoiesis and HSCs using several conditional knockout (CKO) transgenic mouse 
models in addition to the KI/KI mutant mouse model. Here, we report that HSCs from 
surviving adult KI/KI bone marrow (BM) are compromised in their ability to self-renew 
and reconstitute recipient mice. To decipher the possible mechanisms of the KI/KI 
mutation, we utilize our genetic CKO models to conditionally delete Arap3 in 
hematopoietic cells and in several cell types within the HSC niche. Excision of Arap3 in 
hematopoietic cells using Vav-Cre does not alter the ability of ARAP3-deficient HSCs to 
provide multi-lineage reconstitution and to undergo self-renewal, suggesting ARAP3 
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does not play a cell-autonomous role in HSCs. Deletion of Arap3 in osteoblasts and 
mesenchymal stromal cells using Prx1-Cre resulted in no discernable phenotypes in 
hematopoietic development or HSC homeostasis in adult mice. However, reverse 
transplantation into Arap3;Prx1 CKO mice resulted in an expanded phenotypic HSC 
compartment, suggesting ARAP3 plays a crucial role in the BM niche to maintain and 
regulate HSC self-renewal. In contrast, deletion of Arap3 using VEC-Cre resulted in 
embryonic lethality, yet HSCs from surviving adult mice were largely normal and reverse 
transplantation into Arap3;VEC CKO mice revealed HSC frequencies and functions 
comparable to control mice. Taken together, this thesis work suggests that despite a 
critical role for ARAP3 in embryonic vascular development, its loss in endothelial cells 
minimally impacts HSCs in adult BM; however ARAP3 may play a pivotal role in the 
mesenchymal and osteoblastic BM niche to regulate HSC functions. 
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Chapter 1:  
Introduction to ARAP3 and hematopoiesis 
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1. Overview of ARAP3 
1.1 Discovery and characterization of ARAP3  
 ARAP3 is a member of the ARAP (Arf GAP and Rho GAP with ankyrin repeat 
and PH domains) family of proteins, first identified in the cytosol of porcine leukocytes 
in a screen for phosphoinositide-binding proteins (Figure 1.1) [Krugmann et al. 2002]. 
Specifically, ARAP3 was found to bind phosphatidylinositol (3,4,5)-triphosphate (PIP3), 
the lipid second messenger produced by class I phosphoinositide 3-kinases (PI3Ks), with 
high affinity in vitro [Krugmann et al. 2002].  
The interaction between PIP3 and ARAP3 minimally requires the first two 
pleckstrin homology (PH) domains at the N-terminus of ARAP3. This binding is 
strengthened when the N-terminal sterile alpha motif (SAM) domain is included 
[Krugmann et al. 2002, Craig et al. 2010]. Once binding occurs, PIP3 recruits ARAP3 to 
the plasma membrane, where it can act on its GTPase substrates (Figure 1.2). Although 
deletion of any one of its 5 PH domains can abolish ARAP3 binding to PIP3 in vitro 
[Craig et al. 2010], in the context of the full-length protein, a tandem arginine to alanine 
mutation at residues 307 and 308 in the first PH domain (R307,308A) is sufficient for 
complete ablation of PIP3 binding [Krugmann et al. 2002, Craig et al. 2010]. Thus, 
ARAP3 functions in the plasma membrane are mediated by PI3K-dependent PIP3 
production. 
The SAM domain is well-characterized for forming heterodimers, capable of 
recruiting other regulatory proteins into effector complexes [Stapleton et al. 1999, Thanos 
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et al. 1999]. To date, ARAP3 has been found to heterodimerize in a SAM domain-
dependent manner with SHIP2, a negative regulator of PI3K signaling [Pesesse et al. 
1998, Raaijmakers et al. 2007, Leone et al. 2009], as well as Odin and CIN85 [Kowanetz 
et al. 2004, Mercurio et al. 2012]. These proteins are all associated with the regulation of 
the actin cytoskeleton, cell adhesion, and endocytic receptor trafficking [Tong J et al. 
2013, Zheng et al. 2014, Tossidou et al. 2012, Pesesse et al. 1998], all of which are 
known processes regulated by Arf and Rho small G-protein families. Vav2, another 
known regulator of cell migration and endocytosis [Cowan et al. 2005, Marignani and 
Carpenter 2001, Hunter et al. 2006], has been found to interact directly through its Src 
homology 2 (SH2) domain with phosphorylated tyrosine residues in the C-terminal 
region of ARAP3 [Wu et al. 2012].  
ARAP3 is a dual GTPase-activating protein (GAP) with two distinct domains 
targeting Arf and Rho GTPases [Krugmann et al. 2002]. As a dual GAP, ARAP3 acts as 
a negative regulator of these small G-proteins, stimulating the hydrolysis of GTPases in 
their active guanosine triphosphate (GTP)-bound form to their inactive guanosine 
diphosphate (GDP)-bound form (Figure 1.3) [Tcherkezian and Lamarche-Vane 2007]. 
Through in vitro characterization in porcine aortic endothelial (PAE) cells, ARAP3 was 
found to specifically target Arf6 and RhoA GTPases, dependent on the binding of PIP3 
[Krugmann et al. 2002, Krugmann et al. 2004, Krugmann et al. 2006].  
Additionally, its Rho GAP domain is activated in vitro through direct binding of 
Rap GTPase to a weakly conserved Ras association domain at the C-terminal end. 
Studies in Sf9 insect cells show that in the presence of PIP3, binding of Rap-GTP to 
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ARAP3 subsequently induces a two-fold increase in ARAP3 Rho GAP activity, 
indicating PI3K activity is required for Rap-GTP to activate ARAP3 Rho GAP function 
[Krugmann et al. 2004]. The ARAP3 R307,308A mutant abolishes binding to PIP3, 
thereby preventing ARAP3 recruitment to the plasma membrane where it normally acts 
to inactivate its GTPase substrates, Arf6 and RhoA [Krugmann et al. 2002]. Two other 
ARAP family members, ARAP1 and ARAP2, are known. They also bind PIP3 in a PH 
domain-mediated fashion [Craig et al. 2010], though ARAP1 lacks an N-terminal SAM 
domain [Miura et al. 2002]. Despite sharing similar domain structures, they do not share 
the same substrate specificities for GAP activity as ARAP3; ARAP1 targets Arf1 and 
RhoA in vivo, while ARAP2 targets Arf6 but lacks Rho GAP catalytic activity [Yoon et 
al. 2006, Miura et al. 2002]. 
Arf and Rho families of small G-proteins are known to be regulators of cell actin 
cytoskeletal dynamics [Randazzo et al. 2007, Hall 1998]. Therefore, many initial studies 
of ARAP3 involve its manipulation to study the effects on cellular actin remodeling. 
Overexpression in HEK293 human embryonic kidney epithelial cells results in a cell 
rounding phenotype, antagonizing its ability to migrate without affecting its potential for 
adherence on fibronectin-coated surfaces [I et al. 2004]. This effect is ablated with 
expression of a Rho GAP defective mutant of ARAP3 where arginine is mutated to 
leucine at residue 938 (R938L), but not with expression of an Arf GAP defective mutant 
R527K, indicating suppression of cell motility occurs in a Rho GAP-dependent manner [I 
et al. 2004]. Exogenous expression of ARAP3 in PAE cells causes the loss of filamentous 
actin that is exacerbated upon platelet derived growth factor (PDGF) stimulation, 
5 
resulting in a membrane ruffling effect and a retraction of lamellipodia formation 
[Krugmann et al. 2002]. This effect was greatly reduced with expression of either Arf 
GAP or Rho GAP domain mutations, and completely abolished in the presence of both 
GAP mutations together or with expression of the R307,308A mutation [Krugmann et al. 
2002], suggesting a cooperation in catalytic activity of both GAP domains downstream of 
PI3K-mediated ARAP3 regulation of cell morphology. 
Interestingly, when ARAP3 is knocked down using an RNAi-based approach in 
PAE cells, resulting cells also display a cell rounding phenotype and the formation of 
very fine stress fibers [Krugmann et al. 2005]. Since ARAP3 inactivates both its 
substrates Arf6 and RhoA, this implies ARAP3 control of both GTPases is tightly 
regulated, and maintaining precise regulation of ARAP3 levels is crucial to actin 
organization in the cell. Indeed, ARAP3 recruitment to the plasma membrane at sites of 
elevated PIP3 levels is crucial for localized RhoA/Arf6 inactivation and Arf6 cycling, 
both of which are necessary processes during cell migration, adhesion, and cell shape 
regulation [Krugmann et al. 2005, Krugmann et al. 2002, I et al. 2004]. 
1.2 Genetic studies of Arap3 in mouse and zebrafish models 
 Germline deletion of Arap3 in mice results in embryonic lethality at embryonic 
day E11 due to a sprouting angiogenesis defect in vascular development that is not 
apparent in wild-type or heterozygous mice. Explant cultures of Arap3
-/-
 embryos reveal 
vasculogenesis occurs normally in these mice as major blood vessels are able to form in 
early development; however smaller vessels are unable to sprout and reorganize new 
branches of capillaries, indicating the defect is in angiogenesis [Gambardella et al. 2010]. 
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This phenotype is recapitulated with a Tie2-Cre driven conditional knockout mouse 
model of Arap3, further highlighting the endothelial origin of lethality [Gambardella et 
al. 2010]. Additionally, Arap3 deficiency hinders lymphatic vessel development in mice 
and zebrafish through the formation of defective lymphatic endothelial cell precursors. 
Although these precursors are able to initiate the formation of lymphatic vessels from 
pre-existing veins during development, they are deficient in the progression of 
lymphangiogenesis and remodeling of the vascular network [Kartopawiro et al. 2013]. 
 Yolk sacs of Arap3
-/-
 mice appear pale and wrinkly with more narrowed vessels 
compared to their wild-type counterparts. The wrinkly appearance is due in part to a 
loose association of mesodermal and endothelial layers with scattered patches of blood 
cells. However, colony assay analysis revealed no differences between Arap3
-/-
 and 
control yolk sacs, excluding a primitive hematopoietic defect [Gambardella et al. 2010]. 
Definitive hematopoiesis begins later in the mouse embryo, with the first hematopoietic 
stem cell (HSC) arising from the hemogenic endothelium in the aorta-gonad-
mesonephros (AGM) region around E10.5 and later colonizing the fetal liver [Dzierzak 
and Speck 2008]. Thus, definitive hematopoiesis has not been studied in Arap3
-/-
 mice 
due to their early lethality timepoint. 
 Although ARAP3 has been largely unstudied in hematopoiesis, it is abundantly 
expressed in murine hematopoietic tissues [Krugmann et al. 2002, Gambardella et al. 
2010] in addition to strong vascular expression in mice and zebrafish [Gambardella et al. 
2010, Kartopawiro et al. 2014]. A genetic model investigating conditional knockout of 
Arap3 in mouse neutrophils found Arap3 deficiency stimulates a hyper-responsive 
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adherence of neutrophils and subsequently interferes with neutrophil chemotaxis 
[Gambardella et al. 2011]. Thus, ARAP3 does play an active role in at least one cell 
lineage of the hematopoietic system. 
 Arap3 knock-in mutant mice (Arap3
R302,303A/R302,303A
, henceforth referred to as 
KI/KI) also phenocopies Arap3
-/-
 and Arap3
fl/-
;Tie2-Cre knockout mice in their 
vasculature defects and embryonic lethality. The phenotype is not seen in mice 
heterozygous for the mutated allele [Gambardella et al. 2010]. This KI/KI mutation, the 
mouse ortholog of the previously mentioned R307,308A mutation, also ablates PIP3 
binding and recruitment to the plasma membrane, recapitulating the importance of PI3K-
mediated activation of ARAP3 in the mouse in vivo system [Gambardella et al. 2010]. 
KI/KI neutrophils also exhibit deficient chemotaxis and stimulation-induced recruitment, 
mirroring Arap3
-/-
 neutrophils [Gambardella et al. 2013]. Interestingly though, whereas 
Arap3
-/-
 mice are 100% lethal at E11, about 10% of KI/KI mice survive to birth and 
appear grossly normal [Gambardella et al. 2013].  
 Given the importance of ARAP3 in vascular development and the shared 
developmental origin of endothelial and hematopoietic tissues, the study of ARAP3 in 
hematopoietic stem cells will further our knowledge of the field of hematopoiesis. 
2. Overview of Hematopoiesis 
2.1 Hematopoietic stem and progenitor cells (HSPCs) and the HSC niche 
 Hematopoietic stem cells (HSCs) are the critical source of all blood cells because 
they are able to give rise to all mature lineages of the blood system [Warr et al. 2011]. 
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Their potential for self-renewal and multi-lineage repopulation sustains the rapid turnover 
of the blood system throughout life, and is required to replenish multi-potent progenitors 
that give rise to specific hematopoietic lineage-committed precursors [Orkin 1995]. 
These HSPCs are devoted to the differentiation and proliferation of individual lineages of 
the blood, including myeloid cells, lymphoid cells, red blood cells, and 
megakaryocytes/platelets, each regulated by its specific set of hematopoietic growth 
factors or cytokines (Figure 1.4) [Groopman et al. 1989]. 
 HSCs are functionally defined as having the ability for both self-renewal and 
multi-lineage repopulation [Purton and Scadden 2007], classically assessed through bone 
marrow transplantations of HSCs into irradiated recipients. HSCs can be phenotypically 
characterized by a cocktail of cell surface markers that are used to identify and isolate 
HSCs using fluorescence-activated cell sorting (FACS). Specifically, the surface markers 
Lin
-
cKit
+
Sca1
+
 (LSK) define a population that is enriched for HSPCs in mice [Challen et 
al. 2009]. This heterogeneous compartment can further be fractionated by the signaling 
lymphocytic activation molecule (SLAM) markers, CD48
-
 and CD150
+
, or by CD34
-
 and 
Flk2
-
 to define a population enriched for murine long-term HSCs, though different 
surface marker combinations characterize slightly different subsets of relatively pure 
HSC populations [Kiel et al. 2005, Osawa et al. 1996, Adolfsson et al. 2001]. 
 Hematopoiesis in the mouse embryo begins in the yolk sac around embryonic day 
E7.5 with the formation of blood islands known as hemangioblasts [Ferkowicz and Yoder 
2005, Ueno and Weissman 2006]. The hemangioblast is thought to be the common 
source of both endothelial and hematopoietic cells in the developing embryo, giving rise 
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to primitive red blood cells and parts of the yolk sac vasculature [Kinder et al. 1999, 
Kennedy et al. 1997]. Once endothelial development occurs and a network of blood 
vessels and capillaries form in the mouse embryo, the first HSC emerges from the aorta-
gonad-mesonephros (AGM) region of the hemogenic endothelium by undergoing an 
endothelial-to-hematopoietic transition (EHT) around E10.5 [Kissa et al. 2010]. It then 
migrates to and colonizes the fetal liver, the initial site of embryonic definitive 
hematopoiesis. Further colonization of the thymus, spleen, and eventually the bone 
marrow, and expansion of the HSC populations that have migrated to these niches 
together comprise the adult mouse hematopoietic system [Medvinsky and Dzierzak 1996, 
Muller et al. 1994, de Bruijn et al. 2000, Dzierzak and Speck 2008].  
 In the homeostatic adult mouse, HSCs are rare cells that are normally maintained 
in their quiescent non-cycling state [Morrison and Scadden 2014, Passegue et al. 2005]. 
Upon hematopoietic stress such as injury or transplantation into irradiated hosts, they will 
enter the cell cycle to actively differentiate and replenish the required hematopoietic 
lineages [Orkin and Zon 2008]. They reside in and are regulated by complex bone 
marrow (BM) niches that are not mutually exclusive. These specialized 
microenvironments may be composed of multiple cell types that contribute to the niches 
in distinct as well as redundant ways [Ding and Morrison 2013]. Extensive research has 
shown that HSC perivascular and osteoblastic niches are comprised of endothelial cells, 
mesenchymal stromal cells, osteoblasts, sympathetic nerves and non-myelinating 
Schwann cells, all of which contribute either directly or indirectly to the formation and 
maintenance of HSC niches [Calvi et al. 2003, Ding et al. 2012, Ding and Morrison 2013, 
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Yamazaki et al. 2011, Mendez-Ferrer et al. 2008, Katayama et al. 2006, Morrison and 
Scadden 2014]. Genetic studies of HSC niche factors, stem cell factor (SCF) and 
CXCL12 (also known as stromal derived factor-1), reveal the crucial role that the niche 
plays in the retention and maintenance of functional HSCs. When Scf is conditionally 
deleted from the endothelial and perivascular mesenchymal bone marrow niche in mice, 
85% of all long-term multi-lineage reconstituting cells are eliminated, including all 
quiescent HSCs capable of serial transplantable activity [Oguro et al. 2013, Ding et al. 
2012]. When Cxcl12 is deleted from approximately 70% of perivascular mesenchymal 
cells, HSCs mobilize out of the bone marrow niche [Greenbaum et al 2013]. Furthermore, 
HSCs are depleted upon conditional knockout of Cxcl12 in greater than 95% of 
perivascular mesenchymal or endothelial niche cells, but are unaffected by deletion of 
Cxcl12 from osteoblasts or hematopoietic cells [Ding and Morrison 2013, Greenbaum et 
al 2013]. 
2.2 Arf and Rho GAPs in hematopoiesis 
 HSC functions are tightly regulated by a plethora of extrinsic and intrinsic 
regulatory pathways. One such family of regulators is the Rho family of GTPases, 
molecular switches that cycle between an active GTP-bound form and an inactive GDP-
bound form [Etienne-Manneville and Hall 2002, Hall 1998]. Both Arf and Rho GTPases 
outside of the hematopoietic system are known to be master regulators of cell actin 
cytoskeletal dynamics, including control of cell adherence, motility, cell shape, and 
endocytic membrane trafficking [Van Aelst and D’Souza-Schorey 1997, Randazzo et al. 
2000, Murali et al. 2014]. While Arf GTPases have not been studied in hematopoiesis, 
11 
Rho GTPases, including its best studied members RhoA, Rac1, and Cdc42, have been 
found to play pivotal roles in HSPC actin cytoskeletal functions [Mulloy et al. 2010, Gu 
et al. 2003, Gottig et al. 2006, Ghiaur et al. 2006, Florian et al. 2012, Chae et al. 2008, 
Cancelas et al. 2006, Cancelas et al. 2005].  
 Recent genetic studies of the Rho GTPase family in hematopoiesis have expanded 
our knowledge of their roles to include regulation of HSC self-renewal, multi-lineage 
differentiation, homing/migration, proliferation, cytokinesis and survival [Yang et al. 
2007, Guo et al. 2009, Kalfa et al. 2010]. Specifically, conditional knockout of RhoA in 
hematopoietic progenitors leads to a cytokinesis defect resulting in the failure of 
hematopoietic progenitor cells (HPCs) to divide and multiply, thereby causing increased 
HPC necrosis and multilineage hematopoietic failure [Zhou et al. 2013]. RhoA
-/-
 HSCs 
retained their long-term engraftment potential, but could not give rise to any HPCs or 
subsequent mature lineages of the blood [Zhou et al. 2013]. Another study found that 
conditional deletion of RhoA in HSCs aberrantly regulated lymphoid progenitor 
production, reaffirming the requirement for RhoA at the progenitor level for proliferation 
and lineage-specific differentiation [Zhang et al. 2012]. 
 Whereas the role of Rho GTPases in hematopoiesis and cellular functions has 
begun to be understood, the role of Rho GAPs is less well studied. GAPs stimulate the 
hydrolysis of bound GTP to GDP, thereby inactivating their G-protein substrates 
[Tcherkezian and Lamarche-Vane 2007]. One Rho GAP in particular, p190B RhoGAP, is 
a perfect example of the tight regulation under which GTPases need to be controlled in 
vivo. A study shows that loss of p190B in fetal liver HSCs, resulting in the heightened 
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activation of its substrate RhoA, enhances long-term HSC engraftment and self-renewal 
[Xu et al. 2009]. In a separate study, expression of dominant negative RhoA in HSCs also 
enhances engraftment and self-renewal potential [Ghiaur et al. 2006]. These studies of 
RhoA and its negative regulator p190B show similar effects with opposing mechanisms, 
indicating any dysregulation of GTPases results in aberrant functioning. As GAPs are 
increasingly studied, the complex network of tissue- and context-specific activation of 
these GAPs has come to light. There are about two to three times the number of Rho 
GAPs as there are Rho GTPases that they regulate, meaning GTPases often have multiple 
GAP regulators [Tcherkezian and Lamarche-Vane 2007]. Sometimes GAPs can also 
regulate more than one member of a GTPase family, again depending on context and 
tissue specificity [Tcherkezian and Lamarche-Vane 2007]. There are also multi-domain 
GAPs like ARAP3 that target more than one family of small G-proteins, further 
complicating the story and revealing the necessity for continued investigation to enhance 
the understanding of GTPase-activating proteins. 
 Dysregulation of Rho family GTPases and Rho GAPs has been associated with 
multiple human cancers and hematologic disorders such as leukemia, neutrophil 
dysfunction, and Fanconi anemia [Cherfils et al. 2013, Karlsson et al. 2009, Hall 2009, 
Lazer and Katzav 2011, Troeger and Williams 2013, Haneline et al. 1999, Tcherkezian 
and Lamarche-Vane 2007]. Therefore further study of Rho GTPases and their regulators, 
such as GAPs, is crucial to discovering potentially untapped therapeutic value. 
3. Scope and findings of this thesis research 
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 Little is known about how ARAP3 functions in the hematopoietic system. It was 
first identified in pig leukocyte cytosol more than 10 years ago [Krugmann et al. 2002] 
and is highly expressed in endothelial and hematopoietic tissues [Krugmann et al. 2002, 
Gambardella et al. 2010, Kartopawiro et al. 2014], including various cell types and 
subsets of the bone marrow (Figure 1.5). Despite this, ARAP3 has only recently been 
studied in murine neutrophils with regard to the blood system [Gambardella et al. 2013]. 
Arap3
-/-
 mice die early from endothelial defects during embryonic development, 
precluding the study of definitive hematopoiesis in this genetic model [Gambardella et al. 
2010]. Since HSCs first emerge from the hemogenic endothelium during development 
[Dzierzak and Speck 2008], it is intriguing to investigate whether ARAP3 may also play 
a role in hematopoietic stem cells and hematopoiesis. 
 The main purpose of this thesis is to uncover and understand the role that ARAP3 
plays in hematopoiesis and HSPC regulation. This thesis examines both the cell-
autonomous and non-cell-autonomous effects of Arap3 deletion on HSC function, 
utilizing several conditional knockout genetic mouse models (Table 1.1 and Figure 1.6) 
as well as the KI/KI mutant model. 
 Initial in vitro studies of shRNA-mediated knockdown of Arap3 in immortalized 
32D hematopoietic cell lines showed loss of ARAP3 compromised cell proliferation and 
colony formation. Showing promise of a potential regulatory role in hematopoiesis, we 
generated several conditional knockout mouse models of Arap3 to examine how 
hematopoietic-specific and niche-specific deletion of Arap3 affected HSC function. We 
found that ARAP3 is dispensable in HSCs in a cell-autonomous manner. ARAP3 has 
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previously been shown to be a necessary component in the embryonic endothelium 
during development [Gambardella et al. 2010], however we showed that it is not essential 
in the adult mouse endothelium for normal HSC functioning. Additionally, deletion of 
Arap3 in the perivascular stromal and osteoblastic bone marrow niches revealed that 
ARAP3 may potentially play a critical role in the microenvironment to regulate HSC 
expansion and self-renewal, though further studies are necessary to confirm this 
observation. 
 Interestingly, KI/KI mice exhibit impaired HSC engraftment upon transplantation 
and a lineage skewing of repopulated cells, as well as compromised HSC self-renewal 
after serial transplantations. This indicates a necessity of PI3K-coupled ARAP3 
activation for proper HSC functioning that is not apparent when ARAP3 is completely 
ablated within the hematopoietic compartment. Further study is warranted to decipher the 
mechanism of KI/KI HSC functioning and how it differs from Arap3
-/-
 HSCs.  
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Chapter 2: 
In vitro shRNA knockdown of ARAP3 
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1. Introduction 
Little is known about ARAP3 in the hematopoietic system. Despite its early 
discovery in porcine leukocyte cytosol [Krugmann et al. 2002], early studies of ARAP3 
were conducted in endothelial and epithelial cells in vitro to study its roles in actin 
cytoskeletal organization, cell motility, and adhesion [Krugmann et al. 2005, Krugmann 
et al. 2002, I et al. 2004]. Only recently has ARAP3 been studied in neutrophils of the 
blood system, where it has been found to inhibit chemotaxis when ablated [Gambardella 
et al. 2013]. 
Here, we investigate the effects of short hairpin RNA (shRNA)-mediated 
knockdown of Arap3 in vitro in the 32D murine hematopoietic cell line. We also examine 
knockdown of Arap3 in primary mouse bone marrow cells to study whether ARAP3 
plays a physiological role in the murine hematopoietic system. 
2. Results 
2.1 Identification of ARAP3 as a protein of interest 
We first identified ARAP3 from mass spectrometry as a novel binding partner for 
Lnk adaptor protein (Figure 2.1). We confirmed the association between endogenous 
ARAP3 and Lnk by co-immunoprecipitation experiments in the HEL human 
erythroleukemia cell line stably expressing BCR-Abl and Flag-tagged Lnk. The ARAP3-
Lnk interaction is specifically abolished upon treatment with the Abl/Kit/PDFGR 
tyrosine kinase inhibitor Gleevec (Figure 2.2). This coincides with the abrogation of 
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ARAP3 tyrosine phosphorylation by Gleevec. It suggests that this interaction is mediated 
in a tyrosine phosphorylation-dependent manner (Figure 2.2).  
2.2 Screen of shRNAs targeting Arap3 
To begin studying the relevance of ARAP3 in hematopoietic cells, we first 
studied whether ablation of ARAP3 in cell lines would result in a physiological response 
and phenotype. We screened several shRNAs targeted against Arap3 to assess the level of 
knockdown at the protein and RNA levels. ShRNAs employ viral vectors that, when 
infected into mammalian cells such as the 32D hematopoietic cell line, stably integrate 
into the cell genome to ensure long-term knockdown of the target gene [Moore et al. 
2010].  
In the initial screen, we doubly infected 293T cells with murine Arap3 and one of 
five short hairpins (numbered 135-139) targeting Arap3. Upon western blot using an 
ARAP3 antibody, we found reduced levels of ARAP3 expression in cells expressing 
shArap3 136 and 137, and almost complete ablation of ARAP3 expression when short 
hairpins shArap3 138 and 139 were utilized. In contrast, cells infected with shArap3 135 
showed no loss of ARAP3 expression level, comparable to cells expressing either a 
control scrambled short hairpin (scr) or no shRNA at all (Figure 2.3). We then infected 
shArap3 136-139 into 32D murine hematopoietic cells to examine the level of 
knockdown of endogenous mouse Arap3 RNA levels, normalized to Arap3 transcript 
levels in uninfected cells. By quantitative real-time PCR (qRT-PCR), we found robust 
reduction of Arap3 transcript levels using shArap3 136 and 139, while shArap3 137 and 
138 showed partial reduction of transcript levels (Figure 2.4). 
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2.3 Arap3 knockdown inhibits cell growth in vitro 
To study the effects of Arap3 knockdown on cell growth, we infected shArap3 
136-139 into 32D cells stably expressing the myeloproliferative leukemia virus oncogene 
(c-mpl) receptor (32D mpl cells). This cell line responds to both interleukin-3 (IL-3), a 
necessary cytokine to maintain growth of 32D cells [Greenberger et al. 1983], and 
thrombopoietin (Tpo), the growth factor ligand for c-mpl receptor [Kaushansky et al. 
1994, de Sauvage et al. 1994], serving as a tool to investigate cell proliferation. In the 
presence of varying concentrations of murine Tpo and IL-3, we measured the cell density 
using the MTT assay, a colorimetric assay that converts the reduction of MTT compound 
by metabolically active cells into a quantifiable optical density reading on a 
spectrophotometer, correlating into a cell proliferation rate. At concentrations above 
0.1ng/ml murine Tpo or 0.003ng/ml IL-3, there is a significant reduction in cell 
proliferation after Arap3 knockdown with all short hairpins employed, though the 
inhibition appears most severe in shArap3 139-infected cells (Figure 2.5). 
We further examined cell growth in shArap3-infected 32D mpl cells cultured in 
either 1ng/ml murine Tpo or 0.1ng/ml IL-3. Here, we employed short hairpins targeting 
Arap3 that also express green fluorescence protein (GFP). By flow cytometry, we 
measured the percentage of GFP-expressing cells over time as a fraction of the 
percentage of GFP-positive cells on day 0. By day 6, the percentage of GFP-expressing 
cells, indicative of cells in which Arap3 is knocked down, was much lower compared to 
day 0. In contrast, cells infected with the control scrambled short hairpin maintained a 
steady percentage of GFP-expressing cells over time, signifying a decreased rate of 
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growth in shArap3-infected cells (Figure 2.6). When the growth rate of GFP-positive 
cells was quantified by cell count, shScr-expressing control cells grew exponentially 
faster than shArap3-expressing cells by day 6 of culture in either Tpo or IL-3 (Figure 
2.7). 
2.4 Arap3 knockdown attenuates cell cycle progression 
To determine whether knockdown of Arap3 in 32D mpl cells inhibits proliferation 
by increasing apoptosis or slowing down cell cycling, we first looked for the presence of 
apoptotic cells in GFP-positive shArap3-expressing cells after seven days in culture. In 
early to intermediate stages of apoptosis, phosphatidylserines (PS) are translocated to the 
external side of the cytoplasmic membrane, exposing them for detection by fluorescence-
labeled Annexin V antibodies that specifically bind PS. At later stages of apoptosis, the 
integrity of the plasma membrane begins to break apart, exposing nucleic acids to 7AAD 
intercalation and fluorescence [Zimmermann and Meyer 2011]. By flow cytometry using 
AnnexinV and 7AAD, we were able to determine no significant differences in the 
percentage of AnnexinV
+
7AAD
-
 early apoptotic cells or AnnexinV
+
7AAD
+
 late apoptotic 
cells caused by the expression of control shScr or knockdown shArap3 in the GFP-
positive fraction of cells. As a control, we also looked at the percentage of early and late 
apoptotic cells in the GFP-negative fraction and could discern no differences (Figure 2.8). 
Since decreased cell proliferation rate after Arap3 knockdown did not result from 
increased apoptosis, we next examined if there were changes in the cell cycle of shArap3-
expressing cells using a bromodeoxyuridine (BrdU) assay. BrdU is a thymidine analog 
that is incorporated into actively dividing cells during the synthesis phase of the cell cycle 
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that, when used in combination with 7AAD, can pinpoint by flow cytometry the 
particular phase of the cell cycle each cell is undergoing at a static timepoint. After 45 
minutes of BrdU pulse in culture, a larger percentage of shArap3-expressing cells 
remained in G0/G1 phase compared to control shScr-expressing cells in the GFP-positive 
fraction. Correspondingly, there was a decrease in the percentage of shArap3-expressing 
cells in S phase compared to control cells, indicating more cells potentially remained in 
the initial growth phase, progressed through this growth phase more slowly, or were non-
dividing altogether (Figure 2.9). We hypothesize that there may be a possible defect in G1 
to S transition that could have stemmed from knockdown of Arap3. There were no 
changes in the percentage of cells in G2/M phase of the cell cycle. Again as a control, we 
analyzed the GFP-negative fraction of cells that did not express any short hairpins and 
found no changes in the fractions of cells in each phase of the cell cycle. These levels 
were also comparable to those in GFP-positive control shScr-expressing cells (Figure 
2.9). 
To study whether known proliferative signaling pathways were downregulated as 
a result of Arap3 knockdown, we performed a western blot of whole cell lysates from 
32D mpl cells infected with short hairpins that were serum-starved for 3 hours, then 
stimulated for 10 minutes with either 10ng/ml IL-3 or 25ng/ml murine Tpo. We did not 
see any noticeable differences between uninfected cells, control shScr-expressing cells, or 
shArap3-expressing cells in the activation and phosphorylation of STAT5, Akt, or ERK, 
effectors of the JAK-STAT, PI3K, and MAPK signaling cascades, respectively, that 
promote cell growth and proliferation (Figure 2.10) [Weber-Nordt et al. 1998, Kops and 
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Burgering 1999, Seger and Krebs 1995]. Since proliferative pathways are unaffected, it is 
likely that ARAP3 may be affecting members of the cell cycle, potentially through RhoA 
and Arf6, rather than proliferative signaling pathways to regulate cell growth dynamics, 
though we did not measure signaling changes at multiple timepoints nor as a summation 
of activation over time. 
2.5 Arap3 knockdown in primary cells inhibits proliferation 
To evaluate the potential for ARAP3 physiological relevance in hematopoiesis, 
we next studied Arap3 knockdown in primary murine bone marrow cells from wild-type 
C57Bl6/J mice. After isolating and infecting primary cells with control shScr or Arap3-
targeted short hairpins 136 or 139, we tested these cells by qRT-PCR to assess the 
efficiency of Arap3 knockdown and found partial reduction of Arap3 transcript levels in 
shArap3 136-expressing primary cells and near complete ablation of Arap3 transcript 
levels in shArap3 139-expressing primary cells when normalized to control shScr-
expressing cells (Figure 2.11). We cultured these Arap3 knockdown cells in 
methylcellulose to quantify the number of individual colonies that would grow. 
Puromycin was used as a selection marker for 7 days in cells stably expressing the short 
hairpins. When normalized to the number of colonies formed on shScr cultures in four 
independent experiments, there was a marked decrease in the quantity of colonies that 
grew from cells in which Arap3 was knocked down (Figure 2.12). This confirms our 
earlier studies in 32D cells that ARAP3 ablation undermines cell proliferation. More 
importantly, these in vitro studies in primary cells outline the possibility that ARAP3 may 
play an important physiological function in hematopoiesis in vivo. 
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2.6 Arap3 knockdown inhibits repopulation of the hematopoietic compartment upon 
transplantation 
Before moving into in vivo genetic models to study ARAP3 function, we 
performed a bone marrow transplantation (BMT) of GFP- and shArap3- co-expressing 
primary bone marrow cells into irradiated recipient mice. Peripheral blood of the 
recipient mice was evaluated every 4 weeks post-transplant for GFP-positive donor 
chimerism. By 12-16 weeks post-transplant, when reconstitution of the hematopoietic 
compartment in recipient mice is from transplanted long-term HSCs, there is a significant 
reduction of donor chimerism in recipients transplanted with shArap3-expressing bone 
marrow cells compared to control shScr-expressing transplanted recipients (Figure 2.13). 
These experiments involving Arap3 knockdown in primary cells show a potential for 
ARAP3 to play a major role in the regulation of hematopoiesis and HSC function in vivo.  
3. Discussion 
We are the first group to investigate ARAP3 function in vitro in a hematopoietic 
cell line. In this chapter, we employ short hairpin-targeted knockdown of Arap3 to study 
its role in 32D murine hematopoietic cells and primary mouse bone marrow cells.  
We find that Arap3 knockdown constrains cell growth in the presence of growth 
factor Tpo and cytokine IL-3. These cells cycle more slowly, particularly in the G1 to S 
phase transition, after Arap3 knockdown. We would normally proceed to investigate the 
G1/S checkpoint to explore whether any cell cycle regulators are disrupted as a result of 
Arap3 knockdown. However, since this work was done in vitro in a hematopoietic cell 
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line, we first wanted to study whether the same phenotype would manifest in vivo using 
genetic Arap3 knockout mouse models before probing further into the mechanism of 
ARAP3 function on the cell cycle. 
Along these lines, our studies of Arap3 knockdown in primary bone marrow cells 
also show decreased cell growth in colony forming assays in vitro, recapitulating our cell 
line work. Additionally, Arap3 knockdown in primary cells compromises HSC function 
upon transplantation in vivo. Together, our initial investigation into the role of ARAP3 in 
the hematopoietic system shows that knockdown of Arap3 in vitro and ex vivo causes 
defects in normal hematopoietic processes. To verify these results, we must move into 
genetic studies of Arap3.  
It is important to keep in mind that short hairpin-targeted knockdown of Arap3 is 
not the same as genetic deletion of Arap3. ShRNAs, though screened for their ability to 
target the specific gene of interest without affecting other genes, may still have unknown 
off-target effects that could contribute to the phenotypes manifested. Additionally, 
shRNAs do not guarantee a complete ablation of the target gene, as our studies have 
shown. Therefore, what occurs in shRNA-mediated Arap3 knockdown hematopoietic 
cells may not necessarily reflect what would occur in a genetic knockout model of Arap3. 
Using our in vitro knockdown studies as a starting guide point, we next investigate if 
there is a functional correlation when Arap3 is genetically knocked out in mice. 
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Chapter 3:  
Cell-autonomous functions of ARAP3 in HSCs 
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1. Introduction 
Previous studies of Arap3 germline knockout mice show they are embryonic 
lethal at E11 due to an angiogenic defect during embryonic development [Gambardella et 
al. 2010]. Since the first definitive hematopoietic stem cell does not arise from the 
hemogenic endothelium to colonize the fetal liver until approximately E10.5 during 
mouse embryonic development [Dzerizak and Speck 2008], this early lethality precludes 
the study of hematopoiesis and Arap3-deficient HSCs in this genetic model.  
In this chapter, we generated conditional knockout (CKO) mouse models to ablate 
Arap3 in the hematopoietic compartment in order to investigate the role of ARAP3 in 
hematopoiesis and HSCs. Using the Cre-Lox recombination system [Nagy 2000], we 
were able to excise floxed Arap3 alleles [Gambardella et al. 2010] using either Vav 
promoter- or myxovirus resistance-1 (Mx1)-promoter driven Cre recombinase 
expression. Vav is a pan-hematopoietic promoter whose expression begins in the 
developing embryo around embryonic day E11.5 and is fully turned on and expressed in 
greater than 99% of hematopoietic cells in the mouse embryo by E13.5 [Stadtfeld and 
Graf 2004], thereby excising floxed alleles in most, if not all, fetal liver and adult 
hematopoietic cells. Mx1 is a dormant pan-hematopoietic promoter whose active 
expression can be induced by type I interferon or synthetic double-stranded RNA such as 
polyinosine-polycytosine (pIpC) [Kuhn et al. 1995] and can be utilized to study loss of 
targeted genes at desired timepoints. Thus, both the Vav-Cre and Mx1-Cre driven genetic 
knockout models serve as tools to study homeostatic and acute loss of Arap3, 
respectively, in the adult mouse hematopoietic system. 
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2. Results 
2.1 Arap3 is efficiently excised in f/f;Vav mice 
 To begin studying the cell-autonomous function of ARAP3 in hematopoietic 
cells, we crossed floxed Arap3 mice to Vav-Cre mice to mediate Vav-driven excision of 
Arap3 (f/f;Vav). f/f;Vav mice are born alive and in Mendelian ratios, and appear grossly 
normal when compared to their control f/f littermates (data not shown). To measure the 
deletion efficiency at the DNA level, we cultured unfractionated bone marrow cells from 
either f/f;Vav knockout or f/f control mice in methylcellulose colony-forming cell (CFC) 
assays containing cytokines that facilitate multi-lineage differentiation of progenitor cells. 
Each progenitor cell present in the culture gives rise to an individual colony, from which 
DNA is isolated to measure Arap3 deletion efficiency on a clonal basis. Clonal analysis 
by PCR of bone marrow cells harvested from f/f;Vav mice shows complete Vav-Cre-
mediated ablation of Arap3 (Figure 3.1). We also measured Arap3 deletion efficiency at 
the transcript level using qRT-PCR of RNA isolated from f/f;Vav mice, showing greater 
than 95% deletion of Arap3 transcripts in the bone marrow when normalized to transcript 
levels in f/f control mice (Figure 3.2). In contrast, the transcript levels of the other ARAP 
family members, Arap1 and Arap2, remain unchanged in the bone marrow (Figure 3.2). 
Thus, Arap3 is specifically and efficiently knocked out in f/f;Vav CKO mice. 
2.2 ARAP3 is dispensable for steady-state hematopoiesis 
At 6 weeks of age, when adult mice have equilibrated to a homeostatic level of 
hematopoiesis, f/f;Vav mice are indistinguishable from their f/f littermate controls in their 
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peripheral blood composition by complete blood counts (Figure 3.3). At 4-6 months of 
age, the composition of hematopoietic tissues as analyzed by flow cytometry in f/f;Vav 
mice is comparable to that of their littermate controls (Figure 3.4). Since Vav-Cre-
mediated excision begins in early embryonic hematopoietic development and ablates 
Arap3 in all hematopoietic cells of the adult mouse, our data suggests that ARAP3 is 
dispensable for steady-state hematopoiesis in the adult mouse under homeostatic 
conditions. 
After observing no effect on the frequencies of terminally differentiated cell 
populations, we next probed the frequencies of more primitive hematopoietic 
compartments by phenotypic surface marker expression. Within the Lin
-
Sca1
+
cKit
+
 
(LSK) compartment, a heterogeneous population known to be enriched for HSPCs 
[Challen et al. 2009], further fractionation using the SLAM surface markers CD48 and 
CD150 revealed similar percentages of cells in the CD48
-
CD150
+
LSK compartment that 
is enriched for long-term HSCs [Kiel et al. 2005] between f/f;Vav and f/f mice (Figure 
3.5). Furthermore, to evaluate the ability of Arap3-deficient progenitor cells to 
differentiate, proliferate and give rise to colonies of multiple cell lineages in vitro, we 
performed CFC assays with total bone marrow cells or purified LSK cells from f/f;Vav 
and f/f mice. We found no differences in the ability to form various types of colonies with 
normal frequencies (Figure 3.6) and morphology (data not shown) caused by loss of 
Arap3.  
Although Arap3 deficiency in progenitor cells results in no functional differences 
in vitro and ARAP3 is not required for normal hematopoietic development, we show here 
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that Arap3
-/-
 neutrophils from f/f;Vav CKO mice exhibited enhanced polyRGD-induced 
adhesion (Figure 3.7) and increased RhoA activation (Figure 3.8), as previously 
published [Gambardella et al. 2011]. These data together suggest the cell-intrinsic 
functions of ARAP3 may be limited to mature downstream differentiated cells, such as 
neutrophils, rather than in the immature HSPC populations upstream. 
2.3 ARAP3 does not play a cell-autonomous role in HSCs 
Although loss of Arap3 does not confer differences in the ability of the 
heterogeneous LSK population for differentiation and proliferation in vitro, we next 
wanted to probe whether there would be functional differences in Arap3
-/-
 HSPCs in vivo. 
To test these stem cells for multi-lineage repopulating potential and the ability to self-
renew, we performed serial competitive bone marrow transplantation (BMT) assays using 
donor cells derived from f/f;Vav knockout or f/f control mice. Due to differences in 
background strains of the donor and recipient mice, LSK cells were sorted from either 
f/f;Vav or f/f littermate controls (CD45.2
+
) and injected along with whole bone marrow 
cells from SJL competitor mice (CD45.1
+
) into each irradiated F1 recipient mouse 
(CD45.1
+
CD45.2
+
). Peripheral blood of recipient mice was evaluated at 4, 8 and 12 
weeks post-transplantation for donor chimerism and multi-lineage repopulation of the 
irradiated hematopoietic compartment. There were no significant differences in donor 
chimerism of the total blood measured every 4 weeks following the primary transplant 
and in the individual cell lineages within the blood as measured at 12 weeks post-
transplantation (Figure 3.9). Within the donor-derived cells, reconstitution of each cell 
lineage was similarly distributed between Arap3 CKO and control donors (Figure 3.10). 
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Four months after the primary transplant, whole unfractionated bone marrow from 
either f/f;Vav CKO or f/f control cohorts of recipient mice were injected into secondary 
irradiated recipient mice. As before, the peripheral blood was analyzed at 4, 8 and 12 
weeks post-secondary transplantation, and the recipient mice were again found to have no 
drastic differences in HSPC self-renewal and multi-lineage reconstitution upon serial 
transplantation (Figure 3.12). Interestingly, donor chimerism did increase drastically to 
over 80% of repopulated hematopoietic cells (Figure 3.11). However this effect was 
found in secondary recipients of both f/f;Vav and f/f donors, suggesting this may be due to 
an advantage conferred by strain differences between the donor and recipient mice, rather 
than due to the direct loss of Arap3 in the serially transplanted hematopoietic stem cells. 
Thus, despite very efficient deletion of Arap3 at the DNA and RNA levels (Figures. 3.1 
and 3.2), loss of Arap3 resulted in minimal functional impact on HSPCs. 
2.4 f/-;Vav mice recapitulate that ARAP3 is not essential in hematopoiesis 
To rule out any effects that strain differences may be causing in our studies, we 
backcrossed f/f;Vav mice 8 generations onto the pure C57Bl/6J background. Additionally, 
to ensure a more complete and specific deletion of Arap3 in hematopoietic cells, we 
generated Arap3
flox/-
;Vav-Cre (f/-;Vav) mice. These CKO mice showed 100% deletion in 
all f/-;Vav mice we examined at both the DNA and RNA levels (Figures 3.13 and 3.14). 
f/-;Vav mice were also born at normal Mendelian ratios and appeared grossly normal 
(data not shown). Adult f/-;Vav mice showed normal peripheral blood composition by 
complete blood counts (Figure 3.15) and normal lineage distribution of hematopoietic 
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tissues as analyzed by flow cytometry (Figure 3.16) in comparison to f/f and f/- control 
mice.  
In examining the primitive hematopoietic compartments, we found that f/-;Vav 
mice had a normal distribution of CD48
-
CD150
+
, CD48
-
CD150
-
, and CD48
+
CD150
-
 
populations within the HSPC-enriched LSK compartment (Figure 3.17), indicating 
normal phenotypic HSPCs determined by flow cytometry. As in f/f;Vav mice, f/-;Vav 
bone marrow cells did not produce adverse effects on hematopoietic progenitor cell 
proliferation or differentiation in CFC assays (Figure 3.18). Through the phenotypic 
characterization of f/-;Vav mice, we are ensured that ubiquitous loss of one Arap3 allele 
does not affect hematopoiesis and HSPCs, as f/- mice are virtually indistinguishable from 
f/f control mice (Figures 3.13-3.18). 
Despite comparably distributed phenotypic HSPCs between f/-;Vav CKO and f/- 
control mice, we questioned whether this would reflect similar numbers of functional 
HSCs between Arap3
-/-
 and control mice. Through limiting dilution BMT assays using 
unfractionated BM cells, we quantified the frequency of functional HSCs as 1 in 21,215 
bone marrow cells in f/- control mice and 1 in 34,853 bone marrow cells in f/-;Vav CKO 
mice (Figure 3.19), indicating an approximate 1.5-fold reduction in the frequency of 
functional HSCs when Arap3 is ablated in HSCs compared to control mice.  
2.5 Loss of Arap3 does not affect HSC function in serial transplantations 
Although f/f;Vav and f/-;Vav mice are similarly efficient in Arap3 excision, we 
wanted to investigate whether there would be differences in HSC function after 
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transplantation of f/-;Vav LSK cells now that these CKO mice are on a pure background 
and are shown to have a 1.5-fold decrease in HSC frequency. As in earlier experiments, 
we assessed whether ARAP3 plays a role in HSC function in vivo using competitive 
BMT assays. LSK cells sorted from knockout or control mice were transplanted into 
lethally-irradiated recipients and peripheral blood reconstitution was evaluated. Despite a 
lower frequency of f/-;Vav functional HSCs, there were no discernable differences in 
donor chimerism (Figure 3.20) or multi-lineage reconstitution of the peripheral blood 
(Figure 3.21). Serial transplantation also showed normal reconstitution in secondary 
recipients (Figures 3.22-3.23). Together, our studies of Arap3 CKO mice on both mixed 
and pure backgrounds firmly establish that ARAP3 does not cell-autonomously impact 
hematopoiesis and HSPC function under homeostatic conditions. 
2.6 ARAP3 does not play a role in 5-FU-induced stress hematopoiesis 
Though ARAP3 does not seem to play a role in steady-state hematopoiesis, we 
probed whether ARAP3 would act as a critical player when a stress-induced 
hematopoietic response is elicited, as HSPC homeostasis is crucial to tissue maintenance 
and regeneration in response to injury or stress [Geiger and Rudolph 2009, Wilson et al. 
2009]. To invoke a stress response, we injected f/-;Vav CKO and f/- and f/f control mice 
with the pyrimidine analog 5-fluorouracil (5-FU) to eradicate actively dividing cells in 
the blood, causing bone marrow stress in the mice. This forces normally quiescent HSCs 
to enter the cell cycle and undergo rapid expansion and differentiation to repopulate the 
hematopoietic compartment [Harrison and Lerner 1991]. For a period of 29 days after 5-
FU-induced trauma, we observed no differences in hematopoietic recovery between 
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control and knockout mice (Figure 3.24), though there was a slight decrease in white 
blood cell counts at D15 post-injection during the period of peak recovery in f/-;Vav 
mice. This temporary variance may be corroborated by earlier studies showing a 
defective ability of Arap3
-/-
 neutrophils to respond to injury [Gambardella et al. 2011], as 
well as our hypothesis that ARAP3 function may be limited to mature leukocyte lineages 
rather than in the primitive HSPC compartment. 
2.7 Acute loss of Arap3 in adult mice does not impact hematopoiesis or HSC 
function 
After investigating genetic loss of Arap3 during embryogenesis and its impact on 
adult mouse HSCs under homeostatic and 5-FU-induced stress conditions, we next 
explored whether acute loss of Arap3 in adult mice as an alternative form of stress would 
affect HSC function. In these studies, we utilized Arap3
f/f
;Mx1-Cre mice (f/f;Mx1) to 
induce Arap3 excision upon pIpC injection in 2-3 month old CKO and control f/f mice. 
After induced excision, we measured deletion efficiency at the clonal DNA level (Figure 
3.25) and found very efficient deletion in f/f;Mx1 bone marrow cells extending as far as 6 
months post-induction. By qRT-PCR, there remained about 5% Arap3 transcript levels 
when normalized to f/f controls in the bone marrow after Mx1-driven excision, though the 
deletion was specific to Arap3 and not other ARAP family members (Figure 3.26). 
Two weeks post-pIpC induction, we found that both control and CKO injected 
mice showed anomalies in their hematopoietic compartments due to the side effects of 
pIpC (data not shown). Thus, we waited 4-6 weeks post-induction for the mice to return 
to a state of homeostasis before assessing the mice. We found normal complete blood 
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counts in the peripheral blood (Figure 3.27) and lineage distribution within the 
hematopoietic tissues (Figure 3.28), indicating ARAP3 does not play an essential role in 
regulating hematopoiesis despite acute loss in the adult mouse. Moreover, the distribution 
of immature HSPC populations within the LSK compartment was indistinguishable 
between pIpC-induced f/f and f/f;Mx1 mice (Figure 3.29), further confirming that ARAP3 
does not play a role in lineage fate determination and differentiation within the blood 
system. 
To test whether acute loss of Arap3 affects HSC function, we transplanted LSK 
cells isolated from pIpC-treated f/f or f/f;Mx1 mice into irradiated recipients. We found no 
differences in donor chimerism (Figure 3.30) and long-term multi-lineage reconstitution 
(Figure 3.31) in recipient mice up to 16 weeks post-transplant. Therefore, our studies in 
Vav-driven and Mx1-driven Arap3 CKO mice support the conclusion that ARAP3 is not a 
necessary component in the regulation of hematopoiesis and HSC function. 
3. Discussion 
We are the first group to generate a hematopoietic-specific conditional knockout 
mouse model of Arap3 to investigate cell-autonomous ARAP3 functions in 
hematopoiesis. In this chapter, we demonstrate that f/-;Vav conditional knockout mice are 
born alive and healthy, in expected Mendelian ratios, and appear grossly normal. In the 
absence of ARAP3, isolated LSK cells from these CKO mice are not functionally 
different from their control littermate counterparts, whether in vitro by colony-forming 
cell assays or in vivo by competitive bone marrow transplantation. Furthermore, Arap3
-/-
 
hematopoietic stem cells are functionally competent to self-renew and maintain their 
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HSC pool upon serial transplantation despite a lower frequency of functional HSCs in f/-
;Vav mice. This indicates that ARAP3 does not play a major role in HSCs.  
Under stress conditions induced by 5-FU treatment of f/-;Vav mice, we find no 
discernable deficiencies in subsequent hematopoietic recovery. Additionally, acute loss 
of Arap3 in the adult mouse using an inducible Mx1-Cre excision model produces intact 
HSPCs functionally capable of long-term multi-lineage reconstitution upon 
transplantation. Therefore, our studies show that ARAP3 is dispensable for HSC function 
in both homeostatic and stress environments. 
Although ARAP3 is not a critical cell-intrinsic regulator of HSC homeostasis or 
function, it is important to consider that a function for ARAP3 in hematopoietic cells may 
be limited to mature differentiated downstream cells, rather than in HSPCs, as we know 
that ARAP3 already plays an active role in neutrophil adhesion and chemotaxis 
[Gambardella et al. 2011]. The terminally differentiated cells of each lineage of the 
hematopoietic system are the cells most actively utilized physiologically, and thus will 
require the most active regulation of RhoA and the actin cytoskeleton. Just as RhoA 
deletion or use of a dominant-negative RhoA mutant produces different tissue-specific 
phenotypic outcomes [Ghiaur et al. 2006, Xu et al. 2003, del Pozo et al. 1999], ARAP3 
may also have different functions in a context- or tissue-specific manner. It will be 
important to study how pinpointed deletion of Arap3 in lymphoid and non-granulocyte 
myeloid lineages will affect those specific cellular functions. 
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Chapter 4:  
Non-cell-autonomous roles of ARAP3 in the HSC niche 
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1. Introduction 
Hematopoietic stem cells are rare cells that are normally maintained in a quiescent 
state within specific HSC niches [Morrison and Scadden 2014, Passegue et al. 2005]. As 
such, regulation of the microenvironment is a crucial aspect to the maintenance and 
proper functioning of HSCs [Mendelson and Frenette 2014]. There has been much debate 
over the source and composition of the adult HSC niche within the bone marrow stroma 
[Calvi et al. 2003, Ding et al. 2012, Ding and Morrison 2013, Yamazaki et al. 2011, 
Mendez-Ferrer et al. 2008, Katayama et al. 2006, Lymperi et al. 2010, Wang and Wagers 
2011, Morrison and Scadden 2014]. It was originally believed to be osteoblastic in nature 
[Zhang et al. 2003, Calvi et al 2003], though recent advances in the field present strong 
evidence showing osteoblasts do not directly support HSC maintenance in the bone 
marrow [Greenbaum et al. 2013, Ding et al. 2012, Ding and Morrison 2013]. Instead, 
new studies support the existence of stromal HSC niches that are mostly mesenchymal in 
nature and perivascular in localization [Mendez-Ferrer et al. 2010, Sugiyama et al. 2006, 
Pinho et al. 2013, Kunisaki et al. 2013, Nombela-Arrieta et al. 2013]. Some studies also 
reveal an association between HSCs and sinusoidal endothelium in the bone marrow, 
suggesting the endothelium may play a regulatory role within the HSC microenvironment 
[Kiel et al. 2005, Himburg et al. 2012, Hooper et al. 2009]. 
In this chapter, we examine whether ARAP3 plays a role in the HSC 
microenvironment as part of the niche that maintains and regulates HSC quiescence, 
proliferation, and differentiation. To elucidate any potential non-cell-autonomous 
functions of ARAP3 in HSCs, we utilize vascular endothelial cadherin (VEC)-Cre to 
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delete Arap3 in endothelial cells of the HSC niche. VEC-Cre mediates an endothelial cell 
deletion starting just before E8 during embryogenesis [Drake and Fleming 2000], and is 
shown to be more specific to endothelial cells than Tie2-Cre [Kisanuki et al. 2001, Iurlaro 
et al. 2003].  Additionally, because the first HSC arises from the endothelium during 
embryonic development, VEC-Cre deletes Arap3 in all subsequent hematopoietic cells of 
the adult mouse as well (Figure 4.1). We also utilize paired related homeobox-1 (Prx1)-
Cre mice to genetically delete Arap3 in osteoblasts and mesenchymal stromal cells of the 
HSC niche, shown to induce excision in nearly all osteoblasts and 95% of perivascular 
stromal cells in the bone marrow, but not in endothelial cells [Ding and Morrison 2013]. 
2. Results 
2.1 Arap3 is not robustly excised in f/f;VEC mice 
Arap3 has previously been ablated in endothelial cells using Tie2-Cre to study 
ARAP3 in embryonic angiogenic development [Gambardella et al. 2010]. Since Tie2-Cre 
also shows some expression in stromal cells [Kisanuki et al. 2001, Iurlaro et al. 2003], we 
utilized VEC-Cre that is found to be more endothelial cell-specific [Alva et al. 2006, 
Chen et al. 2009]. Arap3
f/f
;VEC-Cre (f/f;VEC) mice were born fertile and at expected 
Mendelian ratios (Table 4.1). This was surprising given the endothelial developmental 
defect that leads to embryonic lethality in germline Arap3
-/-
 mice. However, upon 
analysis of deletion efficiency at the clonal DNA level, we observed an average 80% 
excision rate in f/f;VEC mice (Figure 4.2). By qRT-PCR, approximately 15% Arap3 
transcripts remained in f/f;VEC bone marrow when normalized to levels in control f/f 
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mice, though levels of Arap1 and Arap2 transcripts remain unchanged (Figure 4.3). Thus, 
this model, while specific in targeting Arap3, is inefficient in its excision rate. 
2.2 Residual Arap3 expression in endothelial cells is sufficient for normal 
development 
These f/f;VEC mice appear grossly normal and have similar peripheral blood 
composition from their control littermates at 6 weeks of age (Figure 4.4) and comparable 
hematopoietic tissue composition at 12-16 weeks of age (Figure 4.5). Like f/f;Vav mice, 
f/f;VEC mice exhibit no differences in the ability of bone marrow progenitor cells to 
differentiate and proliferate in CFC assays (Figure 4.6) and have comparable percentages 
of cells in the CD48
-
CD150
+
LSK compartment that is enriched for long-term HSCs 
(Figure 4.7). Upon transplantation of f/f;VEC LSK cells, these cells engrafted and gave 
rise to multi-lineage repopulation of the irradiated hematopoietic compartment in 
recipient mice comparably to transplanted LSK cells harvested from control f/f littermates 
(Figure 4.9). Donor contribution was indistinguishable in all hematopoietic lineages of 
transplanted recipients between f/f;VEC and f/f donor cohorts (Figure 4.8). As expected, 
incomplete loss of ARAP3 did not confer differences in donor chimerism or multi-
lineage repopulation upon secondary transplantation as well (Figures 4.10-4.11). From 
these studies, residual Arap3 expression is sufficient for the emergence of functionally 
normal HSPCs in f/f;VEC CKO mice. 
2.3 ARAP3 expression in endothelial cells is important for embryonic development 
but not in the adult endothelium to support HSC function 
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Earlier studies of Arap3 conditional knockout using Tie2-Cre resulted in 
embryonic lethality only with more robust excision on the f/-, but not f/f, background 
[Gambardella et al Sci Sig 2010]. To obtain a more complete deletion of Arap3 in 
endothelial cells, we generated Arap3
f/-
;VEC-Cre (f/-;VEC) mice. These CKO mice were 
born at a significantly reduced ratio (Table 4.2). The surviving CKO mice appeared 
grossly normal, and showed an average 85% excision efficiency (Figure 4.12), ranging 
from 80% to 95%, compared to an average 80% excision rate in f/f;VEC mice (Figure 
4.2). By qRT-PCR, an approximate 10% Arap3 transcripts remained in f/-;VEC BM 
(Figure 4.13), in contrast to 15% in f/f;VEC BM (Figure 4.3). In agreement with 
previously published data [Gambardella et al. 2010], this indicates that ARAP3 function 
in endothelial cells is essential for embryonic development. 
Surviving f/-;VEC mice were phenotypically normal as characterized by their 
peripheral blood and hematopoietic tissue composition (Figures 4.14-4.15). f/-;VEC bone 
marrow showed similar progenitor proliferation ability in CFC assays (Figure 4.16) as 
well as a normal distribution of HSPCs within the LSK compartment (Figure 4.17) 
comparable to both f/f and f/- controls. By limiting dilution assay, we calculated the 
frequency of functional HSCs in f/-;VEC mice to be 1 in 55,951 bone marrow cells, 
approximately 2.5-fold less than the 1 in 21,215 bone marrow cells HSC frequency in f/- 
mice (Figure 4.18).  
To further explore f/-;VEC HSC functions, we performed competitive serial BMT 
assays. f/-;VEC LSK cells showed largely normal donor chimerism (Figure 4.19) and 
multi-lineage reconstitution (Figure 4.20) in the peripheral blood after transplantation 
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compared to f/- LSK cells. Normal HSC functions were perpetuated in the secondary 
transplants (Figures 4.21-4.22), demonstrating f/-;VEC HSCs are capable of long-term 
self-renewal and multi-lineage repopulation, and are unaffected by the ablation of Arap3 
from the endothelial compartment. Taken together, our investigation establishes that 
despite an essential role for ARAP3 in embryonic vascular development [Gambardella et 
al. 2010, Kartopawiro et al. 2014], ARAP3 loss in endothelial cells does not functionally 
compromise HSCs in adult mouse bone marrow. 
2.4 ARAP3 expression in BM endothelial cells is not required to support HSC 
homeostasis 
To test whether ARAP3 plays a role in the endothelial HSC niche to affect f/-
;VEC HSC function, we performed reverse BMT assays of wild-type bone marrow cells 
from SJL (CD45.1
+
) mice into f/-;VEC irradiated recipients. 8 weeks post-transplant, we 
found similar multi-lineage reconstitution in the peripheral blood (Figure 4.23) and 
percentages of CD45.1
+
 donor-derived LSK and SLAM LSK (CD48
-
CD150
+
LSK) cells 
in the recipient bone marrow (Figure 4.24), indicating no defects in the native f/-;VEC 
HSC microenvironment to support wild-type HSC engraftment, self-renewal, 
differentiation and proliferation. When CD45.1
+
 reconstituted LSK cells were purified 
from primary recipients and transplanted into secondary F1 (CD45.1
+
CD45.2
+
) wild-type 
recipients, there were no differences in the percentage of CD45.1
+
 donor chimerism in 
the repopulated peripheral blood of secondary recipients (Figure 4.25). This demonstrates 
the f/-;VEC microenvironment is capable of supporting and maintaining the long-term 
functional capacity of wild-type HSCs. 
41 
Since HSCs first arise from the endothelium during embryonic development, we 
also examined immunofluorescence images of f/f;VEC and f/-;VEC embryos at E9.5-10.5 
before the lethality timepoint to see whether loss of Arap3 in the endothelium affects 
HSC emergence. These embryos were able to form hematopoietic clusters, indicating 
emergence is not an issue in these CKO mice. Some hematopoietic clusters were 
ectopically expressed throughout the embryo proper in E9.5 embryos, however by E10.5 
hematopoietic clusters were present in the major arteries in the expected proportions and 
quantities (Figure 4.26). It is evident that ARAP3 is critical to embryonic endothelial 
development, as exemplified by delayed vascular development in the E10.5 f/-;VEC 
embryo, possibly resulting in the delay of hematopoietic cluster colonization of and 
localization to the fetal liver (Figure 4.26).  
2.5 ARAP3 may play a pivotal role in Prx1-expressing niche cells to regulate HSC 
self-renewal and expansion 
We next inquired whether ARAP3 plays a role in the osteoblastic and 
mesenchymal stromal cells of the HSC niche using Prx1-Cre driven excision of Arap3. 
Arap3
f/-
;Prx1-Cre (f/-;Prx1) mice were born alive in expected Mendelian ratios and 
appeared grossly normal. Hematopoietic development of f/-;Prx1 mice appeared normal 
as determined by CBC and lineage distribution in hematopoietic tissues, as well as by 
progenitor numbers and function in CFC assays (data not shown). f/-;Prx1 mice also 
exhibited normal frequencies of phenotypic HSCs and progenitors as characterized by 
flow cytometric analysis (Figure 4.27). Using competitive BMT assays, we found that f/-
;Prx1 LSK cells engrafted and repopulated comparably to control f/- LSK cells (Figure 
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4.28). These data indicate that loss of ARAP3 in the stromal and osteoblastic HSC niche 
minimally impacts homeostatic HSC functions in adult mice.  
To determine whether ARAP3 plays a role in the mesenchymal and osteoblastic 
HSC niche to act non-cell-autonomously on HSCs, we performed reverse BMT assays of 
wild-type bone marrow cells into irradiated f/-;Prx1 recipients. We did not ascertain any 
differences in engraftment or multi-lineage repopulation of wild-type HSCs in the f/-
;Prx1 native microenvironment compared to f/- recipients, as assessed by peripheral 
blood reconstitution (Figure 4.29). However, we did observe an expansion of the 
CD45.1
+
 donor-derived SLAM LSK phenotypic HSC population, but not the total 
CD45.1
+
 LSK population in the reconstituted bone marrow (Figure 4.30). This implies an 
important role for ARAP3 in the bone marrow niche to regulate HSC self-renewal, 
expansion, and possibly quiescence. Taken together, these studies suggest that ARAP3 
may non-cell-autonomously regulate phenotypic HSC pool size through its role in Prx1-
expressing niche cells, though assessment of the functionality of these phenotypic HSCs 
by secondary transplantation remains to be determined. 
3. Discussion 
In this chapter, we present the first study of Arap3 genetic deletion in the adult 
mouse endothelium. Previous studies with f/-;Tie2 mice resulted in embryonic lethality at 
E11 similar to germline Arap3
-/-
 mice [Gambardella et al. 2010]. Although Tie2-Cre and 
VEC-Cre are both expressed in early embryonic development in the endothelium around 
E7.5 [Drake and Fleming 2000], their expression patterns and deletion efficiencies are 
slightly different. Tie2-Cre is expressed in a small subset of mesenchymal cells in 
43 
addition to endothelial cells [Kisanuki et al. 2001, Iurlaro et al. 2003] and may give rise 
to a more robust phenotype than VEC-Cre. This is a potential reason why we may see a 
difference between f/-;Tie2 and f/-;VEC live births.  
Here, we present data suggesting that when Arap3 deletion is near 100%, mice are 
embryonic lethal, as is evidenced by the reduced rates of f/-;VEC live births (Table 4.2) 
and in agreement with previously published data [Gambardella et al. 2010]. However, 
when there are residual 5-10% Arap3 transcripts remaining, this is sufficient for 
developing embryos to proceed to live birth and resulting adult mice are phenotypically 
normal. Additionally, a high efficiency of Arap3 deletion in endothelial cells might still 
impact HSCs but may not be apparent in surviving f/-;VEC mice that may have 
upregulated compensatory mechanisms to maintain normal HSC functions under 
homeostatic and stress hematopoiesis situations. Further studies of HSC emergence and 
early development during embryogenesis of f/-;VEC mice may shed some light on the 
potential impact of the loss of ARAP3 in endothelial cells on HSC functions.  
Reverse transplantation of wild-type HSCs into an Arap3-depleted endothelial 
microenvironment did not display altered ability of the host niche to maintain and support 
long-term HSC function.  However, we show for the first time that ARAP3 has a pivotal 
role in the bone marrow stromal microenvironment, particularly in mesenchymal and 
osteoblastic cells. Loss of ARAP3 in the HSC niche of host f/-;Prx1 mice results in 
significantly expanded SLAM LSK compartments upon transplantation of wild-type bone 
marrow cells, while maintaining similar sized LSK compartments as littermate f/- control 
hosts. This implies an important role for ARAP3 in maintaining the phenotypic HSC 
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pool. Secondary transplantation of these phenotypic HSCs into irradiated wild-type 
recipients will show whether this rapid expansion yields functional HSCs capable of 
multi-lineage repopulation of the irradiated hematopoietic compartment. If so, continued 
investigation will elucidate the specific cell type and mechanism through which ARAP3 
acts to regulate HSC engraftment, survival, and self-renewal to induce this rapid 
expansion in the context of an Arap3-deficient niche. 
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Chapter 5: 
Arap3 R302,303A knock-in mutation disrupts HSC function 
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1. Introduction 
The known mechanism of action of ARAP3 on its Arf and Rho GTPase substrates 
is through PI3K-mediated activation upon PIP3 binding and recruitment to the plasma 
membrane [Krugmann et al. 2002, Craig et al. 2010]. PIP3 binding is ablated when a 
tandem arginine to alanine mutation is introduced at residues R302,R303 in the first PH 
domain of the mouse Arap3 allele, preventing ARAP3 activation and subsequent 
recruitment to the plasma membrane [Krugmann et al. 2002, Gambardella et al. 2010]. 
Arap3
R302,303A/R302,303A
 homozygous knock-in mutant mice (KI/KI) phenocopy Arap3
-/-
 
mice, suggesting an essential role for PI3K-dependent activation of ARAP3 
[Gambardella et al. 2010]. 
In this chapter, we investigate the effect of uncoupling PI3K activation from 
ARAP3 function on HSCs and hematopoiesis by employing the KI/KI genetic mutant 
model, in which approximately 2-5% of mice are viable [Gambardella et al. 2013]. 
Viability of rare KI/KI mice is largely dependent upon the background strain of mice. 
After backcrossing 8 generations onto a pure C57Bl/6J background, we found that no 
KI/KI mice survive to live birth. Therefore, all KI/KI mice used for experimentation 
within the scope of this thesis are bred on a mixed Bl6/129 background. 
2. Results 
2.1 KI/KI mice are born alive at a rare rate but appear grossly normal 
When heterozygous KI/+ mice are crossed together, the survival rate is 
approximately 2% of all live births (Tables 5.1-5.2). Figure 5.1 shows representative 
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images of wild-type, heterozygous KI/+, and both viable and non-viable KI/KI mutants at 
E11.5 of embryonic development. The non-viable KI/KI mutant is shrunken and devoid 
of any vasculature or structural development, as magnified at 2x view, while the viable 
KI/KI mutant is nearly indistinguishable from wild-type or heterozygous littermates. 
Flow cytometric analysis of fetal livers from wild-type, heterozygous KI/+, and 
homozygous KI/KI mice at E15.5 show virtually identical distribution of fetal liver 
erythroid progenitors at various stages of maturation (Figure 5.2). When KI/+ mice are 
crossed to KI/KI mice, the rate of KI/KI viability improves to approximately 15% of all 
live births (Table 5.2) 
In analyzing viable KI/KI adult mice, these mice were indistinguishable from 
control mice in gross appearance as well as by phenotypic characterization of their 
peripheral blood by 8-12 weeks of age (Figure 5.3). KI/KI bone marrow also showed 
normal progenitor cell numbers and function as determined by CFC assays (Figure 5.4), 
and normal percentages of SLAM LSK cells enriched for long-term HSCs as determined 
by flow cytometry (Figure 5.5). 
2.2 Arap3 R302,303A mutation impairs HSC functions 
To evaluate the function of KI/KI mutant HSCs, purified LSK cells from KI/KI 
mutant mice or control mice were competitively transplanted into irradiated recipient 
mice. Reconstitution in individual recipient mice was followed every 4 weeks post-
transplant. We found that KI/KI LSKs displayed a significantly lower donor chimerism in 
the total blood (Figure 5.6) as well as all lineages of the peripheral blood (Figure 5.7) in 
reconstituted recipient mice compared to controls, but preserved the lineage distribution 
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within donor-derived cells with a slight skewing towards myeloid reconstitution from 
KI/KI donors (Figure 5.8). Bone marrow of primary transplanted recipients 12-16 weeks 
post-transplantation showed donor-derived cells in total bone marrow as well as the LSK 
and SLAM LSK populations were significantly lower in mice transplanted with KI/KI 
cells, in comparison to control cells (Figure 5.9).  
Four months after the primary transplant, unfractionated bone marrow from 
primary recipients was harvested and injected into secondary irradiated recipient mice to 
further assess HSC function through serial transplantation. Tertiary transplants were 
performed similarly. Peripheral blood and bone marrow HSC reconstitution after each 
transplant was analyzed by flow cytometry. We found that the defects in reconstitution of 
KI/KI cells were exacerbated upon serial transplantations in both the blood and bone 
marrow, indicating compromised HSC self-renewal (Figures 5.10-5.11). Interestingly, the 
initial slight myeloid skewing within KI/KI reconstituted mice from the primary 
transplant manifested into a significant myeloid bias in the multi-lineage reconstitution of 
secondary (Figure 5.12) and tertiary (data not shown) transplanted recipients, reminiscent 
of aged HSCs [Janzen et al. 2006, Rossi et al. 2005, Sudo et al. 2000]. The extent of 
KI/KI HSC functional defects can be summed up in Figure 5.13, showing the declining 
donor chimerism in recipient peripheral blood over the course of serial transplantations. 
2.3 Arap3 R302,303A mutation acts cell-autonomously to inhibit HSC functions 
Since earlier studies of f/-;Vav mice showed no apparent role for ARAP3 in cell-
autonomous regulation of HSC function in the absence of ARAP3, we were interested to 
understand whether the ubiquitously expressed R302,303A knock-in mutation that 
49 
uncouples ARAP3 from PI3K-mediated interaction acts in a cell-intrinsic or non-cell-
intrinsic manner to impede HSC function. 
To investigate whether the knock-in mutation acts non-cell-autonomously within 
the HSC niche to regulate HSC function, we performed reverse transplantation of 
purified wild-type (CD45.1
+
) LSK cells into irradiated KI/KI and control recipients. At 8 
weeks post-transplant, we found similar multi-lineage reconstitution in the peripheral 
blood (Figure 5.14) and percentages of CD45.1
+
 donor-derived LSK and SLAM LSK 
cells in the recipient bone marrow (Figure 5.15), indicating no deficiencies in the KI/KI 
HSC microenvironment to support the engraftment, self-renewal, and multi-lineage 
reconstitution of wild-type HSCs. When CD45.1
+
 reconstituted LSK cells were purified 
from primary recipients and transplanted into secondary F1 (CD45.1
+
CD45.2
+
) wild-type 
recipients, there were no discernable differences in the percentage of CD45.1
+
 donor 
chimerism in the reconstituted peripheral blood of secondary recipients (Figure 5.16). 
This demonstrates the KI/KI mutant microenvironment is capable of supporting and 
maintaining the long-term functional capacity of wild-type HSCs. 
Thus, the Arap3 knock-in mutation likely does not act to negatively regulate HSC 
function through the BM microenvironment, but rather, acts through a cell-autonomous 
mechanism in mutant HSCs. Since the knock-in mutation is ubiquitously expressed in 
KI/KI mice, these studies do not rule out possible non-cell-autonomous effects of the 
R302,303A mutation from sources other than the BM niche to impact HSC function. 
3. Discussion 
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In this chapter, we present the first study of hematopoiesis and HSC function in 
Arap3 KI/KI mice. We show that KI/KI mice exhibit defective HSC functions upon 
transplantation, indicating that PI3K-mediated ARAP3 function is important for HSCs. 
Through reverse BMT studies of wild-type HSCs into the KI/KI host microenvironment, 
we are able to rule out a role for ARAP3 R302,303A mutant in the HSC niche to regulate 
HSC function. Our findings suggest a cell-intrinsic mechanism of action in KI/KI HSCs, 
but does not exclude the possibility of other non-cell-intrinsic signals, for example, such 
as the possibility of the knock-in mutant playing a role in the adult mouse endothelium to 
impact HSCs as was earlier hypothesized with f/-;VEC CKO mice in chapter 4. 
It will be important to further study the KI/KI genetic model, despite the 
difficulties of rare viability associated with utilizing this system, to decipher the 
mechanism of action of the ARAP3 R302,303A mutant. There are a number of possible 
explanations for why we see a difference between cell-autonomous regulation of HSCs in 
KI/KI mice compared to f/-;Vav CKO mice. 1) A developmental delay could result in 
dysregulation of normal homeostatic processes that may indirectly affect HSC 
development, maintenance and function in the adult mouse. 2) Ubiquitous expression of 
the Arap3 R302,303A mutation means ARAP3 could additionally be acting non-cell-
autonomously outside of the HSC niche to regulate HSC function. 3) The ARAP3 knock-
in mutant may sequester or disrupt normal functions of its interacting proteins that may 
directly or indirectly regulate HSC function. 4) ARAP3 R302,303A mislocalization away 
from the plasma membrane could affect other pathways that control HSC function. 5) In 
the absence of intact ARAP3, other compensatory mechanisms may regulate HSC 
51 
function; however in the presence of full-length but mutated ARAP3 protein, it may act 
as a dominant negative mutant. Investigation into each of these possibilities will provide 
answers to shape a more complete model of how ARAP3 functions in the hematopoietic 
system to regulate hematopoietic stem cell function. 
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Chapter 6: 
Conclusions and future perspectives 
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1. Research findings summary 
Prior to this thesis study, ARAP3 has never extensively been studied in the 
hematopoietic system. ARAP3 was largely studied in vitro [I et al. 2004, Krugmann et al. 
2005, Krugmann et al. 2004, Krugmann et al. 2002] and in the endothelium of mouse 
embryonic development [Gambardella et al. 2010]. Only recently has ARAP3 been 
studied in neutrophils through an inducible knockout system [Gambardella et al. 2011, 
Gambardella et al. 2013], however nothing was known about ARAP3 function in the 
process of hematopoiesis and in HSC functions. Consequently, the aim of this thesis is to 
unveil novel knowledge about ARAP3 in the adult mouse blood system. 
The findings presented in this thesis investigate the physiological and functional 
role of ARAP3 in hematopoiesis and hematopoietic stem cell function using novel 
genetic mouse models. Preliminary studies in vitro in hematopoietic cell lines showed the 
potential for ARAP3 to be an important regulator of hematopoiesis, as shRNA-directed 
knockdown studies exhibited a suppressed proliferative phenotype in cell lines and 
primary mouse bone marrow cells. ShArap3-infected primary cells also did not engraft 
and repopulate as efficiently as non-depleted cells upon transplantation. However, the 
limitations of shRNA-mediated knockdown in primary HSPCs include inefficient 
infection rate, inefficient knockdown, and off-target effects. Therefore, we turned to 
genetic ablation of Arap3 using knockout/knock-in mouse models. 
When Arap3 was genetically excised from the mouse hematopoietic compartment 
using Vav-Cre and Mx1-Cre mediated conditional knockout models, the in vitro 
phenotype was not recapitulated in vivo. In fact, HSCs functioned normally in the 
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absence of ARAP3, and we present here that ARAP3 is dispensable for cell-autonomous 
regulation of HSC function or steady-state hematopoiesis. 
In this thesis, we also investigated whether ARAP3 plays a role in the HSC 
microenvironment in the regulation and maintenance of HSC quiescence, self-renewal, 
and proliferative abilities. Arap3 excision from the endothelial niche of the bone marrow 
by VEC-driven Cre recombinase expression did not disrupt the ability of the Arap3-
depleted endothelial niche to support or maintain normal HSC functional abilities. 
However, our findings did uncover a potential importance for ARAP3 in the osteoblastic 
and mesenchymal stromal niches of the bone marrow to support and maintain HSC pool 
size. Arap3 excision from Prx1-expressing cells of the bone marrow microenvironment 
promoted expansion of the phenotypic HSC compartment, suggesting ARAP3 may play a 
role in the niche to regulate HSC quiescence and self-renewal. 
Furthermore, the thesis work presented here also uncovers a detrimental hit to 
HSC functional ability in the presence of an ARAP3 mutant homozygous for the 
R302,303A mutant allele, reiterating the importance of PI3K-mediated activation for 
ARAP3 function. These KI/KI mice display a cell-intrinsic defect in HSC self-renewal 
and multi-lineage reconstitution, though the scope of our studies has not ruled out 
additional non-cell-intrinsic factors that may compound to negatively regulate HSCs, or 
dominant negative effects of this mutation rather than the function of the wild-type 
ARAP3 protein itself. 
This thesis work presents a novel study of ARAP3 in HSCs and the HSC niche. 
Taken together, our findings begin to paint a partial picture of how ARAP3 functions in 
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the hematopoietic system. However, further investigation is warranted to decipher the 
mechanism of ARAP3 action in hematopoietic stem cells and its interplay with ARAP3 
function in the adult bone marrow niche and in the endothelium during embryonic 
development. 
2. Conclusions and future perspectives 
2.1 Cell-autonomous role of ARAP3 in HSCs 
In studying cell-autonomous roles of ARAP3 in HSCs, we found that ARAP3 is 
dispensable in both homeostatic and stress-induced hematopoiesis. We examined both 
steady-state hematopoiesis and 5-FU-induced stress hematopoiesis in f/-;Vav mice and 
found no deficiencies in normal HSC functions and hematopoietic recovery after stress 
such as 5-FU or transplantation. However, our study of ARAP3 during hematopoietic 
stress is by no means exhaustive. Other forms of hematopoietic injury such as 
inflammation, radiation, hypoxia or reactive oxygen species [Signer and Morrison 2013, 
Suda et al. 2011, Mendelson and Frenette 2014] cause different types of damage or stress 
conditions that remain to be examined. It is possible that ARAP3 plays a particularly 
defined context-dependent role in specific hematopoietic stress-induced situations. 
In previous studies of inducibly deleted Arap3-deficient neutrophils, an inducible 
knockout system was utilized wherein a global transient deletion of Arap3 occurs 11-12 
days post-tamoxifen induction [Gambardella et al. 2011]. Arap3 is also acutely deleted in 
our Mx1-Cre inducible system, though there is a much shorter recovery period (11-12 
days as opposed to 4-6 weeks in our f/f;Mx1 mice) before Arap3
-/-
 neutrophils undergo 
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functional tests. The key to revealing a functional role for ARAP3 in HSPCs may thus lie 
in provocation with acute loss and short recovery.  
Therefore, an important consideration is the upregulation of compensatory 
mechanisms that may potentially occur with constitutive loss of Arap3 as opposed to 
acute loss. In our f/-;Vav mouse model, Arap3 is excised during development and CKO 
mice may have an opportunity to activate compensatory mechanisms internally before the 
mouse reaches birth or adulthood. Conversely, with acute Arap3 ablation in f/f;Mx1 mice, 
we observed an influx of change in the hematopoietic system within 2 weeks of pIpC 
injection due to the upregulation of activated interferons. It will be interesting to examine 
HSC function during this 2 week time period to evaluate whether there are functional 
differences. In our studies, we waited for the mice to return to a state of 
equilibrium/homeostasis (4-6 weeks post injection) and proceeded to look for changes in 
HSC function by BMT assay. However, like the Vav-Cre CKO model, perhaps this return 
to homeostasis also triggers other compensatory mechanisms in vivo. Alternatively, pIpC 
induction can be performed 4-8 weeks post-transplantation [Zhou et al. 2013] to 
characterize whether acute ablation of Arap3 in transplanted HSPCs are able to function 
normally and carry out long-term repopulation of irradiated recipients. 
The findings we present from our in vivo cell-autonomous study of ARAP3 do not 
mirror our initial study of Arap3 knockdown in transplanted primary bone marrow cells. 
However, the latter experiments were conducted ex vivo, and may not be reflective of its 
true physiological relevance. ShRNA knockdown studies are also an imperfect system, as 
infection rate and true knockdown of HSCs ex vivo are variable and not 100% efficient. It 
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is also important to consider that shRNAs have off-target effects and are not as specific 
as genetic knockout models. 
This thesis work presents findings showing no apparent role for ARAP3 in HSCs, 
yet previous work shows that ARAP3 plays a role in maintaining neutrophils in their 
quiescent pre-activated state [Gambardella et al. 2011]. Thus, we consider the possibility 
that ARAP3 plays lineage-specific functional roles in downstream mature blood cells 
rather than in the immature HSPC populations in the process of hematopoiesis. In our 
studies, the frequencies of mature lineages in the blood and hematopoietic tissues are 
largely normal at steady-state; however we have not examined mature blood cell 
functions since our studies within the scope of this thesis have focused largely on HSPC 
functions. Further study of Arap3
-/-
 lymphoid cell, monocyte, erythrocyte, and 
megakaryocyte/platelet functions will unveil a comprehensive understanding of whether 
a necessary role for ARAP3 is limited to mature differentiated cell types. 
A more pertinent role for ARAP3 limited to more mature lineages is highly 
plausible in that changes to the cell actin cytoskeleton are actively occurring in these 
cells. For example, neutrophils are attracted to sites of injury or inflammation, where they 
must stop their endothelial rolling movement and extravasate out into the tissue at the site 
of injury [Butcher 1991]. This process of cell mobility, adherence, and extravasation 
requires rapid changes and reorganization of the actin cytoskeleton, and requires high 
coordination of RhoA and Arf6 [Worthylake et al. 2001, Weber et al. 2001]. RhoA has 
been found to be a critical component of proper leukocyte transendothelial migration 
(TEM) [Heemskerk et al. 2014] and epithelial-to-mesenchymal (EMT) transition 
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[Tavares et al. 2006]. Therefore it is likely that RhoA, and in corollary ARAP3, plays an 
important role in cell types that require extravasation or shape shifting, particularly in 
leukocytes such as neutrophils or macrophages. Correspondingly, this is reflected in our 
qRT-PCR analysis of Arap3 expression in the bone marrow that shows the highest Arap3 
message levels in myeloid cells. 
In HSCs, one function that may require RhoA and actin cytoskeletal 
reorganization is the mobilization of HSCs out of the bone marrow niche and into the 
peripheral blood [Korbling et al. 1981, Lemoli and D’Addio 2008], normally in response 
to stress or to maintain a level of homeostasis. HSC mobilization can be tested with G-
CSF stimulation [Wright et al. 2001, Sipkins et al. 2005, Ding et al. 2012] to see if loss of 
Arap3 results in impaired mobilization due to dysregulation of RhoA. 
RhoA has been characterized in vivo to regulate migration and chemotaxis of 
mature hematopoietic cells [Xu et al. 2003, Del Pozo et al. 1999], as well as HSPC 
engraftment, multi-lineage repopulation and cell survival [Ghiaur et al. 2006, Zhang et al. 
2012, Zhou et al. 2013]. ARAP3 is not the only GTPase-activating protein that targets 
RhoA. Other GAPs, such as p190B RhoGAP, are also important regulators of HSPC 
function mediated through its inactivating activity on RhoA [Xu et al. 2009, Raman et al. 
2013]. P190B
-/-
 mice are embryonic lethal, but p190B
-/-
 fetal liver HSCs are functionally 
normal and retain their ability for multi-lineage repopulation upon transplantation, though 
with increased long-term engraftment and repopulation potential over serial 
transplantation [Xu et al. 2009]. However, these mice undergo hematopoietic failure 
during development due to a non-cell-autonomous effect from the loss of p190B in 
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mesenchymal stromal cells of the HSC niche, causing altered bone marrow composition 
and a switch in mesenchymal stem cells to an osteoblastic or adipocytic fate [Raman et 
al. 2013]. While this phenotype is not directly comparable to Arap3
-/-
 mice due to the 
differences in embryonic lethality timepoint, both ARAP3 and p190B are GAPs for 
RhoA, indicating there could be a correlation between these two proteins, their regulation 
of RhoA in the bone marrow niche, and how that regulation affects HSC function. Due to 
the large number of regulators for RhoA, it is likely that each acts in its own individual 
temporal- and spatial-specific manner. The possibility of redundancies between the 
various GAPs also exists [Jeon et al. 2010], such that changing the dynamic by ablating 
one GAP is not enough to alter the process of normal hematopoiesis. It would be 
interesting to investigate whether deletion of multiple GAPs in hematopoietic cells would 
result in greater deficiencies than migration or engraftment alone. 
As a dual GTPase-activating protein, ARAP3 targets Arf6 as well as RhoA. Arf6 
has mostly been studied in non-hematopoietic cells with regard to its role in membrane 
trafficking and the cell actin cytoskeleton [Randazzo and Hirsch 2004, Nie and Randazzo 
2006, Randazzo et al. 2007]. Like RhoA, it is actively involved in cell migration, 
adhesion, proliferation and cytokinesis [Schweitzer and D’Souza-Schorey 2005, 
Knizhnik et al 2011, Randazzo et al. 2000]. However, the potential role of Arf6 in HSPCs 
and hematopoiesis has not been well established. One study showed that the decrease of 
active Arf6-GTP in platelets is critical to the activation of Rho GTPases that is necessary 
for cytoskeletal rearrangements preceding full platelet function [Choi et al. 2006]. It is 
important to further investigate and understand the role of Arf6 in hematopoiesis, 
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particularly in HSCs. It is also important to note that regulators of Arf and Rho GTPases 
engage in crosstalk within their signaling networks [Guilluy et al. 2011, Boulter et al. 
2012, Cherfils and Zeghouf 2013], thus as a regulator of both pathways, ARAP3 may 
interact with various different proteins, either directly or indirectly, to enact its function. 
Therefore, a genetic study of ARAP3 ablation in hematopoietic cells may not be adequate 
to fully uncover its significance and function in the hematopoietic system. 
2.2 Non-cell-autonomous roles for ARAP3 in the HSC niche 
Our studies reveal a potential non-cell-autonomous role for ARAP3 in 
hematopoiesis. Because initial studies in f/-;Tie2 mice [Gambardella et al. 2010] delete 
Arap3 in the endothelium and a small subset of mesenchymal cells during development, 
we investigated whether isolated loss of Arap3 in mesenchymal cells would result in 
HSC defects, both in studying traditional HSC development by looking at native HSC 
function in f/-;Prx1 mice and in studying whether the microenvironment is able to 
support and maintain wild-type HSC functions by reverse transplantation. In our f/-;Prx1 
mice, initial data show that complete ablation of Arap3 in Prx1-expressing cells of the 
bone marrow microenvironment results in an expansion of the SLAM LSK compartment, 
but not the overall heterogeneous LSK compartment, of wild-type donor cells upon 
reverse transplantation, suggesting a role for ARAP3 within the mesenchymal and/or 
osteoblastic niche to influence HSC function non-cell-autonomously. Secondary 
transplantation of these donor-derived LSK cells still needs to be performed to confirm 
whether these expanded SLAM LSK cells are functionally identical to wild-type HSCs. 
Additionally, Mx1-Cre also deletes in a subset of mesenchymal stromal cells and 
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osteolineage cells of the HSC niche [Joseph et al. 2013], though we did not test for 
efficiency of Arap3 deletion in the niche. It would be insightful to perform a reverse 
transplantation of wild-type HSCs into the pIpC-induced f/f;Mx1 microenvironment to 
examine if the same expansion of donor wild-type SLAM LSKs occurs as in f/-;Prx1 
mice. If so, this would affirm an importance for ARAP3 in the BM mesenchymal niche to 
keep HSC self-renewal in check, perhaps as a regulatory mechanism to preserve HSC 
function and prevent premature exhaustion. 
To further dissect the cell types within the BM niche that ARAP3 may be acting 
in to regulate HSC self-renewal and expansion, additional niche cell type-specific genetic 
knockout models can be employed. Prx1 is expressed in 95% of mesenchymal stromal 
cells and nearly all osteoblasts in the BM niche [Ding and Morrison 2013]. To isolate 
these individual cell types, Col2.3-Cre can be utilized to drive excision in osteoblasts, 
Sp7-Cre (Osterix-Cre) to drive excision in osteolineage progenitors and CXCL12-
abundant reticular (CAR) cells, and Lepr-Cre or Nestin-Cre to drive excision in non-
overlapping subsets of mesenchymal stromal cells [Morrison and Scadden 2014, Joseph 
et al. 2013]. Whether ARAP3 is necessary in either or both cell types of the BM niche to 
non-cell-autonomously regulate HSCs can in turn be utilized to decipher its mechanism 
of action. 
Endothelial cells are also a critical component of the BM niche, as HSCs have 
been found to localize perivascularly in the bone marrow [Kiel et al. 2005, Sugiyama et 
al. 2006]. Thus, we utilized VEC-Cre mice to excise Arap3 in endothelial cells, as it has 
been shown to be more endothelial-specific than Tie2-Cre [Kisanuki et al. 2001, Iurlaro 
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et al. 2003, Alva et al. 2006, Chen et al. 2009]. In our f/-;VEC mice, Arap3 is deleted 
from both the endothelial and hematopoietic compartments, and both forward and reverse 
BMTs do not show any significant effects on HSC function due to loss of ARAP3 in the 
endothelium. Additionally, through our limiting dilution assays, we determined the 
frequency of functional HSCs in f/-;Vav mice to be about 1.5x less than in control mice, 
while f/-;VEC mice exhibit about a 2.5-fold reduction in functional HSC frequency. 
However, this decrease in functional HSC frequency did not result in differences in 
engraftment or multi-lineage repopulation upon transplantation of purified LSK HSPCs, 
indicating that the activity of individual HSCs is not affected and therefore can serve to 
repopulate irradiated hematopoietic compartments. It is possible that with extended serial 
transplantation, we may begin to see differences between control and either f/-;Vav or f/-
;VEC donor HSPCs as they begin to exhaust faster, if there are truly less functional HSCs 
within the phenotypic LSK population. It is intriguing that we failed to detect a change in 
phenotypic HSCs by flow cytometry, but found a significant reduction in functional 
HSCs using unfractionated total BM cells, signifying an alteration of surface marker 
expression on HSPCs in these Arap3-excised CKO mice. Perhaps there is only a 
deficiency in stem cell function when there is a limiting dose or frequency of HSCs. 
When a threshold level of functional HSCs is reached, repopulation occurs normally, 
possibly explaining why we observe no differences in reconstitution after transplantation 
of 1000 CKO LSKs in primary and secondary recipients. 
Previous studies [Gambardella et al. 2010] showed that ARAP3 is crucial in the 
mouse embryonic endothelium for angiogenic formation of the vasculature during 
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development. Our data is consistent with this finding. We showed that f/-;VEC mice have 
a drastically reduced survival rate of 10% instead of the expected 25% if born in 
Mendelian ratios. However, what our studies uncover is that ARAP3 is not critical in the 
adult endothelium to support HSCs. Future studies of ARAP3 in the adult endothelium 
need to be undertaken to delineate whether ARAP3 plays an important role in the 
endothelium in non-hematopoietic processes. One way to tease out this answer is to 
separate the variables and isolate Arap3 endothelial deletion during adulthood only, 
instead of creating a conditional knockout model that excises Arap3 during development. 
This can be achieved through an inducible endothelial deletion of Arap3 in adult mice 
using, for example, VEC-Cre-ERT2. In the proposed genetic model, Arap3 would only be 
deleted from the adult endothelium upon tamoxifen induction and would tell us whether 
loss of ARAP3 in the endothelium leads to changes in angiogenesis, or perhaps even in 
HSC function, with acute deletion of Arap3 in the endothelial bone marrow niche. 
However from our reverse transplantation experiments of wild-type cells into f/-;VEC 
microenvironments, it is likely that ARAP3 is not a major non-cell-autonomous regulator 
of HSC functions in adult BM. 
Creating this inducible system will also circumvent the embryonic lethality 
caused by constitutive Arap3 knockout, thus focusing exclusively on the importance for 
ARAP3 in the adult endothelium as opposed to the embryonic endothelium. Because we 
know ARAP3 is such a crucial aspect of endothelial development in the embryo, perhaps 
there are residual effects of high Arap3 deletion efficiency in surviving f/-;VEC embryos 
that carry over to the HSCs that arise from their endothelium. It is possible that the 
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formation of the first HSCs from the endothelium is a deficient process due to loss of 
Arap3, though we know HSC emergence is not an issue from our E10.5 f/-;VEC embryo 
imaging in chapter 4. To test whether HSCs that emerge from the endothelium during 
embryonic development are functionally deficient to begin with, harvested HSCs from 
the fetal livers of E11.5-13.5 embryos can be transplanted into irradiated recipients to 
look for multi-lineage reconstitution and assess whether there is a functional difference in 
initial HSCs that colonize the fetal liver from the endothelium of f/-;VEC knockout and 
f/- and f/f control mice. 
Between f/-;Prx1 and f/-;VEC CKO mice, we have covered a large portion of cells 
thought to contribute to the HSC niche. However, there are other components of the HSC 
niche, including sympathetic nerves, non-myelinating Schwann cells, macrophages, 
CXCL12-abundant reticular cells, and adipoctyes [Calvi et al. 2003, Ding et al. 2012, 
Ding and Morrison 2013, Yamazaki et al. 2011, Mendez-Ferrer et al. 2008, Katayama et 
al. 2006, Morrison and Scadden 2014], that have all been found to be sources and 
contributors to HSC niches in context-dependent manners. Therefore, it will be intriguing 
to continue study of ARAP3 in the BM microenvironment in these other cell types to see 
whether ARAP3 is more broadly essential in the BM niche.  
Our data suggest that ARAP3 might play distinct roles in different cell types. 
ARAP3 plays a positive role in embryonic endothelial cells to support angiogenesis of 
sprouting vessels. ARAP3 might play a positive role in hematopoietic cells to maintain 
HSC activity in limiting doses and surface marker expression, based on our limiting 
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dilution BMT data. Moreover, ARAP3 might play a negative role in BM mesenchymal 
and/or osteoblastic cells to maintain quiescent HSCs and prevent premature self-renewal. 
2.3 ARAP3 R302,303A mutant mice 
Our results demonstrate that the ARAP3 R302,303A mutation (KI/KI) that 
uncouples PI3K-mediated activation and disrupts ARAP3 recruitment to the plasma 
membrane markedly impairs HSC function in a cell-autonomous manner. KI/KI HSCs 
show exacerbated reconstitution defects upon serial transplantations. The potential 
reasons presented earlier in chapter 5 for the difference in KI/KI and f/-;Vav HSC 
phenotypes are: 1) developmental defects, 2) non-cell-autonomous signals from non-
hematopoietic KI/KI cells, 3) binding partners sequestered, 4) mislocalization, or 5) 
dominant negative mutant. We propose a series of experiments to test these possibilities.  
Surviving KI/KI mice are rare, indicating few escape the embryonic lethality that 
results from the inability to form vascular structures during development. The ones that 
do survive may develop aberrantly, particularly with regard to HSC emergence and early 
definitive hematopoiesis that stems directly from the affected vasculature. To bypass this 
developmental issue and to circumvent the high embryonic lethality rate at E11 due to 
defective angiogenic development, we can create an inducible KI/KI model or a 
hematopoietic tissue-specific (i.e. Vav-Cre-ERT2 or Vav-Cre) conditional knock-in 
model to study the effect of the R302,303A mutation specifically in HSCs. In so doing, 
that system would eliminate developmental defects as a potential contributing factor to 
the defective KI/KI HSC phenotype that our studies revealed. This system would also 
tease out whether defective KI/KI HSCs are due solely to cell-intrinsic regulation by the 
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R302,303A mutation or through a combination of cell-autonomous and non-cell-
autonomous signals. Our studies already reveal that the R302,303A mutation in the BM 
niche is likely not contributing to HSC functional impairment, as reverse transplantation 
into KI/KI niches resulted in functionally normal HSCs. Therefore, if an identical 
phenotype arises in hematopoietic-specific KI/KI HSCs, it would indicate the functional 
impairment is cell-intrinsic and not due to developmental issues or non-cell-autonomous 
signals from other cell types. Alternatively, we could also transplant HSCs from KI/KI 
fetal livers to see if they emerge defective during embryogenesis due to developmental 
issues or the early influence of mutant ARAP3 in the embryonic endothelium or other 
cell types that may affect HSC emergence, colonization of the fetal liver, and expansion 
of the HSC pool. 
Another possibility for compromised HSCs in KI/KI mice might be that the 
ARAP3 R302,303A mutant acts in a dominant negative manner to prevent translocation 
of other interacting players (including Vav2, Ship2, Odin, and CIN85) [Kowanetz et al. 
2004, Wu et al. 2012, Leone et al. 2009, Raaijmakers et al. 2007, Mercurio et al. 2013] to 
the plasma membrane, which may affect HSC function. These proteins have largely been 
implicated in motility and endocytic receptor trafficking, but our understanding of their 
functions in hematopoietic cells may be incomplete. Although ARAP3 has not been 
shown to act as a scaffold for the plasma membrane translocation of any interacting 
proteins, and the in vivo relevance of these interactions remains to be tested, the fact that 
we see a cell-intrinsic defect with KI/KI HSCs but not with f/-;Vav HSCs in BMT assays 
speaks in favor of this possibility. It will be crucial to further study binding partners of 
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ARAP3 to see if deletion or dysregulation by the R302,303A mutant affects those protein 
functions. Once a good antibody for ARAP3 immunoprecipitation is developed, the 
identification of potentially more binding partners by mass spectrometry will be possible. 
Additionally, it will be important to study whether other members of the PI3K pathway 
are affected downstream when the PI3K effector ARAP3 is ablated or mutated. We can 
also image KI/KI hematopoietic cells to examine where mutant ARAP3 localizes to in the 
cells, and whether this mislocalization away from the plasma membrane (and the 
potential binding partners it sequesters in the process) also plays a role in how it affects 
HSC function. 
Often, dominant negative mutations are more deleterious than null mutations or 
null alleles. If ARAP3 forms multimers or protein complexes with other potential binding 
partners, such as its in vitro heterodimerization with SHIP2 and Odin or interactions with 
Vav2 and CIN85 suggest [Kowanetz et al. 2004, Wu et al. 2012, Leone et al. 2009, 
Raaijmakers et al. 2007, Mercurio et al. 2013], then the R302,303A mutation could affect 
other signal transduction pathways as well. Since KI/KI uncouples PI3K-mediated 
activation and prevents inactivation of RhoA and Arf6 at the plasma membrane, it will 
also be interesting to observe if point mutations in the RhoA and Arf6 GAP domains of 
ARAP3 [I et al. 2004] will produce null alleles or the same effect as KI/KI HSCs. This 
will ultimately tell us whether ARAP3 function in HSCs has to do directly with its 
function as a dual RhoA/Arf6 GAP, or whether ARAP3 acts indirectly through other 
effectors or binding partners that do not involve its RhoA/Arf6 GAP function. 
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To further dissect the relevance of ARAP3 existence in hematopoietic cells, and 
specifically HSCs, continued study of the processes and functions that its substrates 
RhoA and Arf6 are most actively involved in is necessary. HSCs typically rest in a 
quiescent state, but must be functionally capable of self-renewal and multi-lineage 
reconstitution when circumstances stimulate these functions. RhoA has been found to be 
a critical regulator of mitosis, as its presence is required for cytokinesis of dividing 
HSPCs [Zhou et al. 2013].  Perhaps KI/KI HSCs have a more severe phenotype because 
the mutation prevents mitosis of self-renewing HSPCs and differentiation into mature 
lineages upon transplantation. In f/-;Vav CKO mice, this phenotype could be subtle; in 
the absence of intact ARAP3 protein, the fold increase of activated RhoA in bone marrow 
cells is not even two-fold. The fold change in RhoA activation of KI/KI bone marrow 
cells still remains to be determined. Additionally, when Arap3 is excised during 
development, other compensatory mechanisms or other Rho GAPs may take over to 
control RhoA activation in HSPCs in the absence of ARAP3. However, with the KI/KI 
model, since we believe it is likely acting as a dominant negative mutant, its effects on 
cell division could be magnified in HSPCs that must rapidly expand to repopulate an 
irradiated hematopoietic compartment after BMT. This may explain why initial primary 
BMT recipients exhibit drastically impaired donor chimerism that is perpetuated but not 
further reduced in secondary and tertiary BMT recipients. If mitosis and rapid expansion 
is impaired in KI/KI HSCs, they may exhibit similar longevity as wild-type HSCs. Other 
than mitotic processes during self-renewal and differentiation, HSCs do not involve much 
cell shape or actin cytoskeletal remodeling, the main regulatory roles for RhoA and Arf6 
in vivo. Still, investigating filamentous actin distribution in CKO versus KI/KI HSPCs 
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may provide insight about whether ARAP3 directly, and perhaps in different manners, 
affects actin localization through RhoA and Arf6 regulation in these various transgenic 
mice. 
Although phenotypic SLAM LSK frequencies in KI/KI mice are comparable to 
control mice, it is necessary to perform limiting dilution BMT assays using KI/KI donors 
to quantify the frequency of functional HSCs in these mice. If surface marker expression 
is altered on KI/KI HSPCs, this may partially explain the reduced donor chimerism after 
transplantation with KI/KI LSK donor cells. If HSC frequency remains the same, then 
single cell KI/KI HSC BMTs should be performed to test whether the activity of 
individual KI/KI HSCs is diminished. 
We should also consider the possibility that KI/KI HSCs are impaired in their 
ability to home to the recipient BM niche upon transplantation, perhaps due to 
impairments in mobilization, homing to the proper niche signals, or adherence to the 
niche itself [Ghiaur et al. 2006, Xu et al. 2009]. This is an alternative explanation for why 
donor chimerism is low in the primary recipient, but does not dramatically worsen over 
serial transplantations nor does it affect multi-lineage reconstitution initially. Therefore, 
investigating the number of donor KI/KI HSPCs that home to the bone marrow within 48 
hours of transplantation [Yusuf and Scadden 2009] will provide a clearer understanding 
of KI/KI HSC functional impairment. In corollary, G-CSF stimulated mobilization of 
KI/KI HSCs out of the bone marrow niche and into the peripheral blood will also help 
clarify whether the R302,303A mutation hinders HSC mobility. 
2.4 Other considerations 
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To understand whether other compensatory mechanisms and protein expression 
may be upregulated in the absence of ARAP3, the next step would be to investigate 
expression levels of other RhoA and Arf6 regulators and effectors when ARAP3 is 
ablated or mutated. Along these lines, ARAP3 is part of a dual-GAP family that also 
includes ARAP1 and ARAP2. Although ARAP1 and ARAP2 have been found to target 
different GTPase substrates and have varying catalytic activity, they both show high 
expression in peripheral blood leukocytes and hematopoietic tissues, though Arap2 
message levels were not detected in bone marrow [Miura et al. 2002, Cuthbert et al. 
2007, Yoon et al. 2006]. Thus, these three proteins may have overlapping and redundant 
roles in hematopoiesis, and may work in conjunction to regulate HSPC function. It will 
be interesting to see whether crosstalk of their respective substrate pathways can maintain 
normal HSC function in the absence of ARAP3. Thus, genetic studies of mice deficient in 
Arap1 or Arap2, or with combination deletions of multiple ARAP proteins would clarify 
whether there is a significant role and an additive effect for the ARAP family of proteins 
together in hematopoiesis. 
Although ARAP3 was first purified from porcine leukocytes for its PIP3 binding 
ability [Krugmann et al. 2002], and is highly expressed in hematopoietic tissues 
[Krugmann et al. 2002, Gambardella et al. 2010], our studies show that ARAP3 is not a 
critical cell-intrinsic regulator of hematopoiesis. ARAP3 does not play a cell-autonomous 
role in regulating HSC homeostasis or function, though it is important in the embryonic 
endothelium and likely in the bone marrow niche to maintain and support adult HSPCs. 
Based on proposed future experiments, new results will clarify whether other 
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compensatory mechanisms and proteins compensate for ARAP3 function in HSCs and 
whether ARAP3 in the hematopoietic system is directly influenced by its presence in the 
adult endothelium. We will also be able to delineate the mechanism of KI/KI action, and 
isolate the variables to separate and explain the different phenotypes in CKO and KI/KI 
adult mice versus during embryonic development. 
Lastly, ARAP3 has been implicated in the regulation and progression of several 
human diseases, including defense against bacterial infection, diabetes and gastric 
carcinoma, by capitalizing on the ability of ARAP3 to manipulate vesicle internalization 
and cell invasion [Lu et al. 2004, Nandy et al. 2009, Yagi et al. 2011]. Dysregulation of 
Rho family GTPases and their regulators have also been correlated with human blood 
disorders and tumorigenesis [Cherfils and Zeghouf 2013, Karlsson et al. 2009, Hall 2009, 
Lazer and Katzav 2011, Troeger and Williams 2013]. While aberrant expression of 
ARAP3 has not yet been found in blood disorders, its ability to regulate the actin 
cytoskeleton makes it a potential target for the dysregulation of homeostatic cell 
functions. Thus, continued study of ARAP3 in normal and abnormal hematopoiesis will 
be important to elucidate a more comprehensive understanding of its role in the blood 
system, including in the HSC microenvironment. 
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Generation of Arap3 transgenic mice 
Arap3
flox/flox
 (f/f) and Arap3
KI/KI
 (KI/KI) mice were generated as described 
previously [Gambardella et al. 2010]. Vav-Cre mice were originally generated by Dr. 
Thomas Graf [Stadtfeld and Graf 2004] and backcrossed to C57Bl/6J background for 8 
generations. VEC-Cre mice were kindly provided by Dr. Nancy Speck [Chen et al. 2009] 
and backcrossed to C57Bl/6J background for 8 generations. These two strains of mice, 
along with Mx1-Cre, were crossed to generate f/+;Cre mice, which were then crossed to 
f/f mice to generate f/f;Cre conditional knockout mice. Initial studies in f/f;Vav, f/f;VEC, 
and f/f;Mx1 mice were done in mixed Bl6/129 background, while later studies in f/-;Vav 
and f/-;VEC mice were performed on a pure C57Bl/6J background following 
backcrossing for 8 generations. f/+ mice on the pure C57Bl/6J background were crossed 
with CMV-Cre mice on the C57Bl/6J background (The Jackson Laboratory) to generate 
Arap3
+/-
 (+/-) mice. These mice were used to generate f/-;Vav mice, f/-;VEC and f/-;Prx1 
conditional knockout mice (all on a pure Bl6 background) that will ensure a more 
complete deletion efficiency. Prx1-Cre and Mx1-Cre mice on a C57Bl/6J background 
were purchased from The Jackson Laboratory. Wild-type SJL (CD45.1
+
) used for 
transplantations were also purchased from The Jackson Laboratory. 
The animal studies were carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health. The protocol was approved by the Institutional Animal Care 
and Use Committee of the Children’s Hospital of Philadelphia. 
PCR genotyping and qRT-PCR  
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For genotyping and clonal PCR analysis, primers were generated to detect 
wildtype, floxed and deleted alleles of Arap3 using DNA isolated from CFU-C assays or 
mouse tissues. PCR reactions were performed on a BioRad thermal cycler using the 
following primers for Arap3: 5’-AGAGGCTCAGGACTAGAAGGACTA-3’ 
(Arap3_461F) and 5’-GGGCTGAGTAGAGACT GACGCGCC-3’ (Arap3_EcorV_F) 
and 5’-GAGGCCAGCCTGAGATAGATGAAACCC-3’ (Arap3_EcorV_R) in a 
0.15:1:0.5 ratio. 
For quantitative real-time PCR, total RNA was isolated from FACS-sorted bone 
marrow cells, CFC assays or hematopoietic tissues using Trizol Reagent (Invitrogen Life 
Technologies) followed by isolation with the RNeasy Mini kit (Qiagen). cDNAs were 
produced using BioRad iScript kit and qRT-PCR reactions were performed on an Applied 
Biosystems 7900HT real-time PCR system using Sybr-Green detection with the 
following primers: Arap3: 5’–CCCTCTGACTGCCATCGA–3’ and 5’–ATTCCAGGTC 
ATTACCGGCC–3’; Arap1: 5’-GATGCCGCACTGTCTGTAGCT-3’ and 5’-CTGCTCA 
AAGAGTGCCGTGTAC-3’; Arap2: 5’-CGGGACGAATGGCGTATTAG-3’ and 5’-
TCTCGCCCTGAAACTGAAAGA-3’; Gapdh: 5’–GGAGCGAGACCCCACTAACA–3’ 
and 5’–TTCACACCCATCACAAACAT–3’. The transcript levels in CKO mice were 
first normalized to Gapdh levels, then expressed as a percentage of normalized levels in 
control f/f mice. 
Complete blood counts 
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Peripheral blood was collected by retro-orbital bleeding into capillary blood 
collection tubes with EDTA (Becton Dickinson). CBC analysis was performed using the 
mouse setting on a HemaVet 950 machine (Drew Scientific). 
Cell sorting and flow cytometry  
Cells from either peripheral blood or hematopoietic tissues were lysed of red 
blood cells, then stained with surface markers on ice and washed in PBS with 2% bovine 
calf serum. Surface markers used to identify cell populations are: CD3e-PE for T-cells, 
CD19-APC for B-cells, Gr1-PE and Mac1-APC for myeloid cells (eBiosciences), and 
propidium iodide for viability. This method was also used for peripheral blood analysis of 
transplanted mice with the addition of CD45.1-PE-Cy7 and CD45.2-FITC antibodies. 
Fetal liver cells were stained with CD71-PE and Ter119-PE-Cy7 (eBiosciences) and 
analyzed by flow cytometry for erythroblast stages. Flow cytometry was performed on a 
FACS Canto analyzer (Becton Dickinson). 
For HSPC analysis, total bone marrow cells were flushed from femurs, tibias and 
iliac crests of mice. Single-cell suspensions were lysed of red blood cells and stained with 
the following primary antibodies: biotinylated lineage cocktail (B220, CD4, CD5, CD8, 
CD19, IL-7R, Gr1, Mac1, Ter119), Sca1-PerCP-Cy5.5, cKit-APC-Cy7, CD48-FITC, and 
CD150-PE-Cy7 (eBiosciences). Cells were then washed in PBS with 2% bovine calf 
serum and stained with streptavidin-PE-TexasRed secondary antibodies. DAPI was used 
for viability. Immunophenotypes were defined by signaling lymphocytic activation 
molecule (SLAM) family markers [Kiel et al. 2005] CD48
-
CD150
+
LSK (SLAM LSK) as 
a population enriched for long-term HSCs. CD48
-
CD150
-
LSK and CD48
+
CD150
-
LSK 
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populations are enriched for HPCs. Flow cytometry was performed on a LSR Fortessa 
analyzer (Becton Dickinson). 
For cell sorting, bone marrow cells were first depleted of lineage-positive cells 
using biotinylated lineage cocktail and streptavidin-coupled Dynabeads (Invitrogen) per 
manufacturer’s protocol. Lineage-negative (Lin-) cells were then stained for LSKs as 
described above and sorted on a FACS Aria Cell Sorter (Becton Dickinson). All analysis 
of FACS data was performed using FlowJo software (TreeStar). 
Colony-forming cell (CFC) assays 
Unfractionated bone marrow cells or sorted LSK cells were plated at a 
concentration of 15,000-20,000 or 200 cells per plate, respectively, in duplicate using 
semisolid methylcellulose (Methocult M3434, StemCell Technologies) containing SCF, 
IL-3, IL-6 and erythropoietin. Cells were incubated at 37°C, 5% CO2 with high humidity, 
and colonies were enumerated after 10-12 days in culture.   
Competitive bone marrow transplantation (BMT) and serial BMTs 
Bone marrow cells (CD45.2
+
) were harvested and sorted for LSK surface markers 
as described above. 500-1000 LSK cells were mixed with 3-4x10
5
 competitor bone 
marrow cells (CD45.1
+
) and injected into each lethally-irradiated (a split dose of 10Gy, 
137
Cs source) [Bersenev et al. 2008] F1 recipient mouse (CD45.1
+
CD45.2
+
). Donor-
derived reconstitution in the periphery was measured by flow cytometry every 4 weeks 
post-transplant. At 12-16 weeks, recipient mice were sacrificed and analyzed for donor 
HSPCs, as described above with the addition of CD45.1-PE and CD45.2-APC antibodies. 
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For secondary transplantation, 2x10
6
 unfractionated bone marrow cells from pooled or 
individual primary recipient mice were transplanted into lethally irradiated F1 recipients. 
Reconstitution was again measured every 4 weeks post-transplant and data of secondary 
transplant endpoints are shown where mentioned. Tertiary transplants were performed 
similarly.  
Reverse bone marrow transplantations 
In reverse BMTs, 1x10
6
 total bone marrow cells from CD45.1
+
 wild-type donor 
SJL mice were transplanted into lethally irradiated f/f and f/- controls or f/f;VEC, f/-;VEC, 
and f/-;Prx1 (CD45.2
+
) CKO recipients. Donor-derived reconstitution in the peripheral 
blood and the percentage of CD45.1
+
 LSK and SLAM LSK cells in the bone marrow of 
recipients was measured 8 weeks after transplantation. 2,000-3,000 CD45.1
+
 LSKs were 
sorted from primary recipients and competitively transplanted along with 3.5x10
5
 F1 
(CD45.1
+
CD45.2
+
) bone marrow cells into irradiated F1 secondary recipients. Donor-
derived reconstitution was measured in the peripheral blood of secondary transplant 
recipients every 4 weeks post-transplant. 
For KI/KI reverse BMTs, 10
4
 LSK cells were sorted from SJL mice and 
transplanted along with 3x10
5
 F1 competitor cells into KI/KI or KI/+ irradiated 
recipients. Reconstitution and donor-derived HSPCs were measured as described above. 
Secondary transplants into F1 irradiated recipients were also performed as described 
above. 
Limiting dilution competitive BMT assay 
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 For each BMT experiment, bone marrow cells from control and CKO mice of 
each genotype were serially diluted, mixed with 3.5×10
5
 CD45.1
+
 competitors, and 
subsequently transplanted into lethally irradiated recipient mice. We analyzed peripheral 
blood chimerism 3-4 months after transplant, and mice with either over 1% donor-
derived cells in each lineage or over 1% in total donor-descent (CD45.2
+
) cells in the 
peripheral blood were counted as positive reconstitution [Szilvassy et al. 1990]. 
Calculation of competitive repopulation units was conducted using L-Calc software 
(StemCell Technologies).  
Immunofluorescence and imaging of embryos 
 Whole embryos were removed from pregnant dams on specified days of 
embryonic development. After dissection, embryos were fixed with 2% 
paraformaldehyde on ice for 20 minutes, then washed three times in cold PBS for 10 
minutes. The embryos were then kept in 50% methanol on ice for 10 minutes, followed 
by 100% methanol on ice, and stored at -20°C in 100% methanol until staining. Embryos 
were stained using CD31 for endothelial cells and Runx1 for hematopoietic clusters. 
Images were taken on a confocal microscope. 
5-fluorouracil (5-FU) hematopoietic stress challenge and recovery 
 Mice were intraperitoneally injected with a single dose of 150mg/kg 5-FU on D0. 
Retro-orbital and tail vein blood was alternately taken on days 0, 2, 5, 8, 11, 15, 21, and 
29 after administration and assessed by CBC for recovery.  
Neutrophil adhesion assay 
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 Neutrophils were isolated from 2-3 month old mice. Femurs and tibias were 
flushed with calcium- and magnesium-free Hank’s Balanced Salt Solution (Life 
Technologies) with 1% bovine serum albumin (HBSS solution) to prevent neutrophil 
activation. Cells were centrifuged at 400g for 10 minutes at 4°C. Pelleted cells were lysed 
of erythrocytes and washed with HBSS solution and resuspended in 1-3ml of HBSS 
solution. Cells were loaded onto a three-layer Percoll gradient (81%, 62%, 55% 
Amersham) diluted in HBSS, then centrifuged at 1500g for 30 minutes at room 
temperature. Neutrophils were harvested from the 81%/62% interface and washed with 
2ml HBSS solution. Neutrophils were then resuspended in HBSS solution at a 
concentration of 10
6
 cells/ml and used for adhesion assay within 6 hours. 
 For adhesion assays, 24 well non-tissue culture plates (Nunc) were pre-coated 
with 20ug/ml polyRGD or blocked with heat inactivated bovine calf serum (Invitrogen) 
for 1 hour at 37°C. Bone marrow-derived neutrophils were prewarmed for 5 minutes at 
37°C, then 5x106 cells were plated on these 24 well plates for 30 minutes at 37°C before 
washing three times with PBS and enumerating the number of adherent cells per field of 
view at 20x magnification on a light microscope.  
RhoA-GTP pull-down assay 
 RhoA-GTP was assessed by a RhoA Pull-down Activation Assay Biochem Kit 
(Cytoskeleton) according to the manufacturer’s instructions. Unfractionated bone marrow 
cells were lysed in buffer containing 0.5% NP-40, phosphatase, and protease inhibitors. 
GTP-bound RhoA was then immunoprecipitated from protein supernatants with 
glutathione S-transferase-tagged Rhotekin-Rho-binding domain protein bound to 
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glutathione agarose. The beads were washed and precipitates were blotted with a 
monoclonal antibody against RhoA. Lysates were blotted with RhoA as a control. 
Cell culture and growth assays 
 32D murine hematopoietic cells with or without mpl expression were stably 
infected with short hairpins targeting Arap3 (OpenBiosystems) or a control scrambled 
shRNA. Short hairpins contained a puromycin resistance gene or were engineered to co-
express GFP. Cells were cultured in varying concentrations of thrombopoietin or 
interleukin-3 where indicated.  
 To assess proliferation, shRNA-infected cells were either selected by puromycin 
for 7 days and then counted every 2 days afterwards on a hemacytometer (Hausser 
Scientific), or analyzed every other day by flow cytometry for co-expression of GFP. For 
MTT assays (Promega), the protocol was conducted according to the manufacturer’s 
protocol. Cells were plated at a concentration of 10
5
 cells/ml in 96-well tissue culture 
plates in the presence of cytokines and allowed to proliferate at 37°C for 24-48 hours. 
15ul of the Dye Solution was then added to the wells and allowed to incubate at 37°C for 
4 hours, at which time 100ul of Stop Solution was added to each well and incubated 
overnight at room temperature. Absorbance was read at 570nm using a 96-well plate 
reader (Molecular Devices). 
Annexin V assay 
 Assays were carried out in accordance with manufacturer’s protocol (BD 
Pharmingen). 32D cells infected with short hairpins co-expressing GFP were cultured for 
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4-7 days. Cells were collected and pelleted by centrifugation, then washed twice with 
cold PBS and resuspended in 1X Binding Buffer at a concentration of 10
6
 cells/ml. 100ul 
of cells were transferred to a 5ml culture tube and 5ul of Annexin V and 5ul of 7-AAD 
was added to the tube, then mixed and incubated for 15 minutes in the dark at room 
temperature. 400ul of 1X Binding Buffer was added to each tube and cells were analyzed 
by flow cytometry on a FACS Canto analyzer (Becton Dickson). 
Bromodeoxyuridine (BrdU) cell cycle analysis 
 BrdU assays using the APC BrdU Flow Kit (BD Pharmingen) was carried out 
according to manufacturer’s protocol. 32D cells infected with short hairpins co-
expressing GFP were cultured in the presence of BrdU at a final concentration of 10uM 
for 45 minutes at 37°C. BrdU-pulsed cells were then harvested and washed in 1ml of cold 
PBS. Pelleted cells were resuspended in 100ul of BD Cytofix/Cytoperm Buffer and 
incubated at room temperature for 20 minutes. Cells were washed with 1ml BD 
Perm/Wash Buffer and then resuspended in 100ul of BD Cytoperm Plus Buffer for 10 
minutes on ice. Cells were again washed with 1ml BD Perm/Wash Buffer and 
resuspended in 100ul BD Cytofix/Cytoperm Buffer and incubated for 5 minutes at room 
temperature. Cells were washed with 1ml BD Perm/Wash Buffer and resuspended in 
100ul of DNase diluted to 300 ug/ml in PBS, then incubated for 1 hour at 37°C. Cells 
were washed with 1ml BD Perm/Wash Buffer, resuspended in 50ul of BD Perm/Wash 
Buffer containing APC-BrdU antibody, and incubated at room temperature for 20 
minutes. Cells were washed in 1ml BD Perm/Wash Buffer and resuspended in buffer 
containing 7-AAD solution, then analyzed by FACS Canto analyzer (Becton Dickinson). 
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Western blot 
 32D culture cells infected with short hairpins targeting Arap3 were washed and 
starved in RPMI with 0.5% BSA for 2 hours. The cells were either left unstimulated or 
stimulated with 25ng/ml Tpo or 10ng/ml IL-3 for 10 minutes. Cells were then lysed in 10 
mM Tris-Cl (pH 7.4), 150 mM NaCl, and 1% NP-40, containing 2 mM each of NaF and 
Na3V2O4 plus protease inhibitors (Roche). The samples were run on SDS-PAGE gels 
and transferred onto Nitrocellulose membranes. The blots were then probed with the 
following antibodies: anti-Stat5 (C-17) rabbit polyclonal antibodies (Santa Cruz 
Technology Inc.) and anti–pStat5 (Tyr694), pMAPK (Thr202/Tyr204), p42/44 MAPK, 
pAkt (Thr473), and Akt antibodies (Cell Signaling Technology). Unstimulated cells were 
also probed for ARAP3 expression using sheep anti-ARAP3 antiserum [Krugmann et al. 
2002]. 
Statistics 
 Statistical analysis was performed using two-tailed Student’s t tests. P values of 
less than 0.05 were considered significant. 
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Tables 
Cre strains Expression 
Vav-Cre 
Turns on around E11.5 in embryo; expressed in more than 99% 
of hematopoietic cells by E13.5; deletes in all hematopoietic 
cells [Stadtfeld and Graf 2004] 
Mx1-Cre 
Interferon-inducible expression; expressed in all hematopoietic 
cells, a subset of bone marrow mesenchymal stromal cells 
including more than 50% of nestin+ cells, perivascular cells, 
and osteolineage cells; expressed in other tissues including 
liver, kidney, and heart [Park et al. 2012, Kuhn et al. 1995, 
Joseph et al. 2013] 
VEC-Cre
 
 
Turns on around E7.5-E8 in embryo; deletes in all endothelial 
cells and hematopoietic cells [Drake and Fleming 2000, Chen 
et al. 2009, Alva et al. 2006] 
Prx1-Cre 
Turns on around E9.5 in embryo; deletes in 95% of 
mesenchymal stromal cells, mostly all osteoblasts, and 50% of 
the PDGFRa+Sca1+ mesenchymal stem cell population [Ding 
and Morrison 2013, Greenbaum et al. 2013, Logan et al. 2002] 
 
Table 1.1. Expression of various promoter-driven Cre in Arap3 conditional 
knockout mouse models. 
 
f/f;VEC f/+;VEC f/f f/+ 
f/f x f/+;VEC 
30/142 
(21.1%) 
37/142 
(26.1%) 
36/142 
(25.3%) 
39/142 
(27.5%) 
Expected ratios 25% 25% 25% 25% 
 
Table 4.1. f/f;VEC live birth rates. Breeding pairs are labeled in the left column. 
Genotypes of expected pups are labeled at the top of each column. Birth rates are 
displayed as a percentage and fraction of total pups born alive. Expected Mendelian ratios 
are listed below each cross breeding. 
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f/-;VEC f/f;VEC f/- f/f 
f/- x f/f;VEC 
14/136 
(10.3%) 
30/136 
(22.1%) 
45/136 
(33.1%) 
47/136 
(34.6%) 
Expected ratios 25% 25% 25% 25% 
 
Table 4.2. f/-;VEC live birth rates. Breeding pairs are labeled in the left column. 
Genotypes of expected pups are labeled at the top of each column. Birth rates are 
displayed as a percentage and fraction of total pups born alive. Expected Mendelian ratios 
are listed below each cross breeding. 
 
KI/KI KI/+ +/+ Notes 
E10.5 1 5 4 1 KI/KI dead 
E11.5 4 3 2 3 KI/KI dead 
E12.5
 
 0 5 0  
E13.5 0 5 1  
E14.5 0 10 6  
E15.5 1 6 1  
 
Table 5.1. KI/KI embryo survival analysis. Embryos from KI/+ x KI/+ matings 
examined for genotype. Embyonic age of embryos labeled in the left column. Genotypes 
of embryos/pups are labeled at the top of each column. Notes indicate when KI/KI 
embryos were found to be embryonic lethal in utero. 
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KI/KI KI/+ +/+ 
KI/+ x KI/+ 2/110 (1.8%) 68/110 (61.8%) 40/110 (36.4%) 
Expected ratios 25% 50% 25% 
KI/+ x KI/KI
 
 38/243 (15.6%) 205/243 (84.4%) -- 
Expected ratios 50% 50% -- 
 
Table 5.2. KI/KI live birth rates. Breeding pair genotypes are displayed in the left 
column. Genotypes of expected pups are labeled at the top of each column. Birth rates of 
each genotype are displayed as a percentage and fraction of total pups born alive. 
Expected Mendelian ratios of each genotype are listed below each cross. 
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Figures 
 
Figure 1.1. ARAP3 structural domains. SAM = sterile alpha motif, PH = pleckstrin 
homology, GAP = GTPase-activating protein, RA = Ras association domain. 
 
Figure 1.2. PI3K-mediated ARAP3 activity in vivo. PIP3 binds the N-terminus of 
ARAP3 in a PI3K-mediated fashion and recruits ARAP3 to the plasma membrane where 
it can act on its substrates, Arf6 and RhoA small GTPases. 
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Figure 1.3. GAP proteins inactivate GTPases. Small GTPases act as molecular 
switches that cycle between an active GTP-bound form and an inactive GDP-bound form. 
GAP proteins hydrolyze GTP to GDP, thus inactivating the GTPase. 
 
89 
Figure 1.4. Classical hematopoietic hierarchy. Long-term stem cells retain the ability 
to self-renew and give rise to all lineages of the blood. Multi-potent progenitor cells 
differentiate into lineage-committed progenitor, eventually giving rise to all mature 
lineages of the hematopoietic system. 
 
Figure 1.5. Arap3 transcript expression in the bone marrow. Arap3 transcript levels in 
various cell types and subsets of wild-type mouse bone marrow were measured by 
quantitative real-time PCR (qRT-PCR), normalized to levels of Gapdh. Cells were sorted 
based on the following surface marker expressions: hematopoietic = CD45
+
, stromal =  
CD45
-
Ter119
-
VEC
-
PDGFRab
+
, endothelial = CD45
-
Ter119
-
VEC
+
PDGFRab
+
, myeloid = 
Gr1
+
 and Mac1
+
, lymphoid = CD3
+
 and CD19
+
, erythroid = Ter119
+
, HSPCs = Lin
-
Sca1
+
cKit
+
 (LSK), long-term HSCs = CD48
-
CD150
+
LSK. 
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Figure 1.6. Promoter expression of Arap3 CKO mice in various cell types of the HSC 
niche. Vav-Cre expresses in all hematopoietic cells. VEC-Cre mediates excision in all 
endothelial and hematopoietic cells. Prx1-Cre ablates in osteoblasts and mesenchymal 
stromal cells. Mx1-Cre deletes in all hematopoietic cells as well as a subset of 
mesenchymal stromal cells/osteolineage cells upon interferon induction. 
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Figure 2.1. Identification of ARAP3 as a protein of interest. Tandem Affinity 
Purification (TAP) of epitope- tagged Lnk in hematopoietic cell lines followed by mass 
spectrometric analysis. Through this approach we identified ARAP3 as a novel Lnk 
binding partner. 
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Figure 2.2. Lnk interacts with endogenous ARAP3. HEL B/A cells stably expressing 
Flag-tagged Lnk were either treated with vehicle control or Gleevec 6 hrs before lysis. 
Lysates were precipitated with anti-ARAP3 antibodies followed by WB with anti- Flag, 
4G10 and ARAP3 antibodies sequentially (top panel), or precipitated with anti-Flag 
antibodies followed by WB using anti- ARAP3, 4G10, and Lnk antibodies (bottom 
panel). pY: phospho-tyrosine; C: IgG control. 
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Figure 2.3. shArap3 knockdown efficiency. 293T cells were infected with exogenous 
mouse ARAP3 protein, and either one of 5 different short hairpins targeting Arap3 or a 
control scrambled short hairpin (scr). Whole cell lysates were blotted for ARAP3 
expression, with tubulin as a loading control. 
 
Figure 2.4. shArap3 knockdown efficiency of endogenous mouse Arap3 transcripts 
in 32D cells. 32D murine hematopoietic cells were infected with shArap3. Cell lysates 
were assayed by qRT-PCR for level of Arap3 transcripts remaining, normalized first to 
the housekeeping gene Gapdh, and then normalized to Arap3 transcript levels in 
uninfected cells. 
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Figure 2.5. MTT growth assay of 32D mpl cells infected with shArap3. 32D cells 
were infected with control shScr or short hairpins targeting Arap3, then grown in culture 
with increasing concentrations of mouse thrombopoietin (top panel) or interleukin-3 
(bottom panel). Cell density was measured by MTT assay. 
95 
 
Figure 2.6. shArap3 growth assays by GFP percentage. 32D mpl cells were infected 
with short hairpins co-expressing GFP, then cultured in 1ng/ml mTpo (top panel) or 
0.1ng/ml IL-3 (bottom panel) for 6 days. The percentage of GFP
+
 shRNA-expressing 
cells was measured every two days, and is represented as a fraction of the percentage of 
GFP
+
 cells on D0 of culture. 
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Figure 2.7. shArap3 growth assays by cell count. 32D mpl cells were infected with 
short hairpins and cultured in 1ng/ml mTpo (top panel) or 0.1ng/ml IL-3 (bottom panel) 
for 6 days. Cell counts were measured every 2 days in culture. 
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Figure 2.8. Apoptosis in 32D cells expressing shArap3. 32D cells were infected with 
short hairpins co-expressing GFP, then assayed for apoptotic cells by flow cytometry 
using AnnexinV and 7AAD as markers. The top panel shows percentage of apoptotic 
cells within the GFP
+
 shArap3- or shScr-expressing fraction of cells. The bottom panel 
shows percentage of apoptotic cells within the GFP
-
 control uninfected fraction of cells. 
n.s. = not significant. 
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Figure 2.9. Cell cycle analysis of 32D cells expressing shArap3. 32D cells were 
infected with short hairpins co-expressing GFP, then assayed by flow cytometry using 
BrdU and 7AAD as markers for the percentage of cells in each phase of the cell cycle, 
defined by the gates shown in the top panel. The middle panel shows percentage of cells 
within each phase of the cell cycle in the GFP
+
 shArap3- or shScr-expressing fraction of 
cells. The bottom panel shows percentage of cells in each phase within the GFP
-
 control 
uninfected fraction of cells. 
 
Figure 2.10. Changes in signaling pathways upon cytokine stimulation of 32D cells 
infected with shArap3. 32D mpl cells were infected with short hairpins and stimulated 
for 10 minutes with either 10ng/ml IL-3 or 25ng/ml mTpo. Shown are western blots of 
whole cell lysates for changes in phosphorylation and activation of STAT5, Akt, and 
ERK. 
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Figure 2.11. shArap3 knockdown efficiency in primary bone marrow cells. Murine 
bone marrow cells infected with shArap3 were assayed by qRT-PCR for the level of 
Arap3 transcripts remaining, normalized first to the housekeeping gene Gapdh, and then 
normalized to Arap3 transcript levels in shScr-infected cells. 
 
Figure 2.12. shArap3 knockdown on colony-forming abilities of primary cells. 
Murine bone marrow cells infected with shScr or shArap3 were plated on methylcellulose 
cultures (CFC assays) and enumerated after 11 days. Shown are total colony counts 
normalized to shScr cultures from 4 independent experiments. 
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Figure 2.13. Donor chimerism after transplantation of bone marrow cells infected 
with shArap3. Murine bone marrow cells were infected with control (scr) or Arap3-
targeting (136, 139) short hairpins co-expressing GFP, then transplanted into irradiated 
mice. GFP% was measured by flow cytometry in the cells on D0 before transplantation, 
then every 4 weeks post-transplantation in the peripheral blood of reconstituted recipient 
mice. 
 
Figure 3.1. Clonal analysis of f/f;Vav mice bone marrow deletion efficiency. 
Representative PCR genotyping results of individual colonies from CFC assays of f/f;Vav 
bone marrow cells are shown. Controls are tail DNA isolated from control and CKO 
mice. The top band is floxed Arap3 while the bottom band reflects deleted Arap3. 
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Figure 3.2. qRT-PCR analysis of f/f;Vav bone marrow deletion efficiency. RNA 
transcript levels from f/f;Vav mice bone marrow were assayed by qRT-PCR for the 
relative transcript levels of Arap1, Arap2, and Arap3 remaining compared to that in f/f 
controls. Each symbol represents an individual mouse; horizontal lines indicate mean ± 
SEM levels. 
 
Figure 3.3. Complete blood counts of f/f;Vav mice peripheral blood. CBC of f/f 
control (white bars) and f/f;Vav CKO mice (black bars). n=17. Graphs show mean ± 
SEM. 
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Figure 3.4. Lineage distribution in f/f;Vav hematopoietic tissues. Flow cytometric 
analysis of the percentage of various cell populations in the BM, spleen, and thymus of f/f 
and f/f;Vav mice. n=17. Graphs show mean ± SEM. 
 
Figure 3.5. CFC assays of f/f and f/f;Vav bone marrow cells. 15,000 total bone marrow 
cells (left panel) or 200 LSK cells (right panel) were plated in methylcellulose CFC 
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assays and enumerated after 11 days in culture. n=17 and 3, respectively. Colonies 
identified as multipotent myeloid progenitors (GEMM), erythroid (BFU-E), granulocyte-
monocyte progenitors (GM), granulocyte (G), or monocyte (M). Graphs show mean ± 
SEM. 
 
Figure 3.6. SLAM LSK percentage in f/f;Vav mice. The percentage of SLAM LSK 
population enriched for long-term hematopoietic stem cells in f/f and f/f;Vav bone 
marrow, gated on the Lin
-
c-Kit
+
Sca1
+
 (LSK) population, followed by SLAM markers 
CD48
-
CD150
+
. Horizontal lines show mean ± SEM. 
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Figure 3.7. Adherence of f/f;Vav neutrophils. Poly-RGD induced adherence of bone 
marrow-derived neutrophils from f/f and f/f/;Vav mice was quantified in triplicate as the 
number of cells per field of view at 20x magnification. Graphs show mean ± SEM. P-
values determined by two-tailed Student’s t-test. 
 
Figure 3.8. RhoA-GTP pulldown assay of f/f;Vav bone marrow. Bone marrow cells 
from f/f and f/f;Vav mice were assayed for levels of active RhoA-GTP by western blot 
(left panel) and the fold change in expression was quantified using ImageJ and 
normalized to the levels of RhoA-GTP in f/f bone marrow (right panel). RhoA in the 
lysates was blotted as a control. 
106 
 
Figure 3.9. f/f and f/f;Vav primary BMT peripheral blood assessment for donor 
chimerism. Primary transplantation of LSK cells from f/f and f/f;Vav donor mice. 
Peripheral blood of recipient mice assessed at 4, 8, and 12 weeks after primary 
transplantation for the percentage of donor-derived leukocytes (left panel). Donor 
contribution to myeloid, B-cell, and T-cell compartments in the peripheral blood at the 
end of the primary transplants was analyzed by flow cytometry (right panel). Results 
pooled from 3 separate experiments. Myeloid: Mac1
+
; B-cells: CD19
+
; T-cells: CD3
+
. 
Graphs show mean ± SEM. 
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Figure 3.10. f/f and f/f;Vav primary BMT peripheral blood assessment for lineage 
distribution. Bars show lineage distributions within CD45.2 donor-derived cells of 
individual recipient mice (left Y-axis), while diamond symbols indicate total donor 
leukocyte percentages (right Y-axis) in the peripheral blood, at the end of the primary 
transplants. T: CD3
+
; B: CD19
+
; M: Mac1
+
. Results pooled from 3 separate experiments. 
 
Figure 3.11. f/f and f/f;Vav secondary BMT peripheral blood assessment for donor 
chimerism. Secondary transplantation of total bone marrow from primary BMT 
recipients. Peripheral blood of recipient mice assessed every 4 weeks after secondary 
transplantation for donor-derived leukocytes (left panel). Donor contribution to myeloid, 
B-cells, and T-cells in the peripheral blood at the end of the secondary transplants was 
analyzed by flow cytometry (right panel). Results pooled from 3 separate experiments. 
Myeloid: Mac1
+
; B-cells: CD19
+
; T-cells: CD3
+
. Graphs show mean ± SEM. 
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Figure 3.12. f/f and f/f;Vav secondary BMT peripheral blood assessment for lineage 
distribution. Bars show lineage distributions within CD45.2 donor-derived cells of 
individual recipient mice (left Y-axis), while diamond symbols indicate total donor 
leukocyte percentages (right Y-axis) in the peripheral blood, at the end of the secondary 
transplants. T: CD3
+
; B: CD19
+
; M: Mac1
+
. Results pooled from 3 separate experiments. 
 
Figure 3.13. Clonal analysis of f/f;Vav and f/-;Vav bone marrow deletion efficiency. 
Representative PCR genotyping results of individual colonies from CFC assays of f/-;Vav 
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and f/f;Vav CKO mice. Controls are tail DNA isolated from f/f, f/- and f/-;Vav mice, 
showing the Arap3 floxed band (top band) and the Arap3 deleted band (bottom band). 
 
Figure 3.14. qRT-PCR analysis of f/f;Vav and f/-;Vav bone marrow deletion 
efficiency. Arap3 RNA transcript levels from BM of f/-, f/f;Vav, and f/-;Vav mice were 
assayed by qRT-PCR and first normalized to Gapdh levels. The graph shows the relative 
Arap3 transcripts remaining in the CKO mice compared to that in f/f controls. Each 
symbol represents an individual mouse; horizontal lines indicate mean ± SEM levels. 
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Figure 3.15. Complete blood counts of  f/-;Vav mice peripheral blood. CBC of f/f 
(white bars), f/- (crosshatch bars), and f/-;Vav (black bars) mice. n=8. Graphs show mean 
± SEM. 
 
Figure 3.16. Lineage distribution in f/-;Vav hematopoietic tissues. Percentage of 
various cell populations in the BM and spleen of f/f, f/-, and f/-;Vav mice was analyzed by 
flow cytometry, as defined by the surface markers indicated. n=5. Graphs show mean ± 
SEM. 
 
Figure 3.17. CFC assays of f/-;Vav bone marrow cells. CFC assays of f/f, f/-, and f/-
;Vav BM cells were enumerated after 11 days in culture. n=8. Graphs show mean ± SEM. 
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Figure 3.18. Percentage of HSPC populations in f/-;Vav bone marrow. Percentage of 
various HSPC populations in the BM from f/f, f/-, and f/-;Vav mice was quantified using 
flow cytometry, defined by Lin
-
Sca1
+
c-Kit
+
 (LSK) and the SLAM markers CD48 and 
CD150. n=5. Graphs show mean ± SEM. 
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Figure 3.19. HSC frequency in f/-;Vav mice. HSC frequencies quantified using limiting 
dilution BMT assays of total bone marrow cells from f/- and f/-;Vav mice. Peripheral 
blood of recipient mice were analyzed 3-4 months after transplantation, with mice over 
1% donor chimerism in every lineage of the blood (top panel) or over 1% in total donor-
derived cells (bottom panel) counted as positive reconstitution. HSC frequencies: top 
panel: 1 in 42,188 (f/-), 1 in 83,779 (f/-;Vav); bottom panel: 1 in 21,215 (f/-), 1 in 34,853 
(f/-;Vav). Results pooled from 3 independent experiments. 
 
Figure 3.20. Vav CKO primary BMT peripheral blood assessment for donor 
chimerism. Primary transplantation of LSK cells from f/f and f/- control or f/f;Vav and f/-
113 
;Vav CKO donor mice. Peripheral blood in the recipients was assessed at 4, 8, and 12 
weeks after primary transplant from control (CTL = f/f and f/-, white bars) and CKO (KO 
= f/f;Vav and f/-;Vav, black bars) donor mice by flow cytometry for the percentage of 
donor-derived cells. Data pooled from 3 independent experiments. n=8-15. Graphs show 
mean ± SEM. 
 
 
Figure 3.21. Vav CKO primary BMT peripheral blood assessment for lineage 
distribution. Bars show lineage distributions within donor-derived cells of individual 
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recipient mice (top panel) or the average of all recipient mice (bottom panel) at the end of 
the primary transplants. T: CD3
+
; B: CD19
+
; M: Mac1
+
. Graphs show mean ± SEM. 
 
Figure 3.22. Vav CKO secondary BMT peripheral blood assessment for donor 
chimerism. Secondary transplantation of total bone marrow from primary BMT 
recipients. Peripheral blood of recipients assessed at the end of the secondary transplant 
for donor chimerism by flow cytometry. CTL = f/f and f/-, white bars; KO = f/f;Vav and 
f/-;Vav, black bars. Data pooled from 3 independent experiments. n=8-15. Graphs show 
mean ± SEM. 
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Figure 3.23. Vav CKO secondary BMT peripheral blood assessment for lineage 
distribution. Bars show average lineage distributions within donor-derived cells of all 
recipient mice at the end of the secondary transplants. T: CD3
+
; B: CD19
+
; M: Mac1
+
. 
Graphs show mean ± SEM. 
 
Figure 3.24. Hematopoietic recovery following 5-FU-induced stress. f/f, f/-, and f/-
;Vav mice peripheral blood was assessed by CBC for 29 days following 5-FU injection. 
Results pooled from 2 independent experiments, n = 9-18. 
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Figure 3.25. Clonal analysis of f/f;Mx1 mice bone marrow deletion efficiency. 
Representative PCR genotyping results of individual colonies from CFC assays of 
f/f;Mx1 bone marrow cells are shown after pIpC induction. Controls are tail DNA isolated 
from control and CKO mice. The top band is floxed Arap3 while the bottom band reflects 
deleted Arap3. 
 
Figure 3.26. qRT-PCR analysis of f/f;Mx1 bone marrow deletion efficiency. RNA 
transcript levels from f/f;Mx1 mice bone marrow were assayed by qRT-PCR for the 
relative transcript levels of Arap1, Arap2, and Arap3 remaining compared to that in f/f 
controls after pIpC induction. Bars show mean ± SEM levels. 
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Figure 3.27. Complete blood counts of f/f;Mx1 mice peripheral blood. CBC of f/f 
control (white bars) and f/f;Mx1 CKO mice (black bars) after pIpC induction. n=7. 
Graphs show mean ± SEM. 
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Figure 3.28. Lineage distribution in f/f;Mx1 hematopoietic tissues. Flow cytometric 
analysis of the percentage of various cell populations in the BM, spleen, and thymus of f/f 
and f/f;Mx1 mice after pIpC induction. n=5. Graphs show mean ± SEM. 
 
Figure 3.29. Percentage of HSPC populations in f/f;Mx1 bone marrow. Percentage of 
various HSPC populations in the BM from f/f and f/f;Mx1 mice was quantified using flow 
cytometry, defined by LSK and the SLAM markers CD48 and CD150. n=5-7. Graphs 
show mean ± SEM. 
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Figure 3.30. f/f and f/f;Mx1 primary BMT peripheral blood assessment for donor 
chimerism. Primary transplantation of LSK cells from f/f and f/f;Mx1 donor mice. 
Peripheral blood of recipient mice assessed at 4, 8, and 16 weeks after primary 
transplantation for the percentage of donor-derived leukocytes. Graphs show mean ± 
SEM. 
 
Figure 3.31. f/f and f/f;Mx1 primary BMT peripheral blood assessment for lineage 
distribution. Bars show average lineage distributions within donor-derived cells of all 
recipient mice at the end of the primary transplants. T: CD3
+
; B: CD19
+
; M: Mac1
+
. 
Graphs show mean ± SEM. 
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Figure 4.1. VEC-Cre mediates Arap3 excision in all endothelial and hematopoietic 
cells. The first HSC emerges from the hemogenic endothelium around E10.5 during 
development. Since vascular endothelial cadherin (VEC) expression turns on just before 
E8 during embryogenesis, this model deletes in all endothelial and hematopoietic cells. 
 
Figure 4.2. Clonal analysis of f/f;VEC mice bone marrow deletion efficiency. 
Representative PCR genotyping results of individual colonies from CFC assays of 
f/f;VEC bone marrow cells are shown. Controls are tail DNA isolated from control and 
CKO mice. The top band is floxed Arap3 while the bottom band reflects deleted Arap3. 
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Figure 4.3. qRT-PCR analysis of f/f;VEC bone marrow deletion efficiency. RNA 
transcript levels from f/f;VEC mice bone marrow were assayed by qRT-PCR for the 
relative transcript levels of Arap1, Arap2, and Arap3 remaining compared to that in f/f 
controls. Each symbol represents an individual mouse; horizontal lines indicate mean ± 
SEM levels. 
 
Figure 4.4. Complete blood counts of f/f;Vav mice peripheral blood. CBC of f/f 
control (white bars) and f/f;VEC CKO mice (gray bars). n=12. Graphs show mean ± 
SEM. 
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Figure 4.5. Lineage distribution in f/f;VEC hematopoietic tissues. Percentage of 
various cell populations in the BM, spleen, and thymus of f/f and f/f;VEC mice. n=12. 
Graphs show mean ± SEM. 
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Figure 4.6. CFC assays of f/f and f/f;VEC bone marrow cells. Methylcellulose colony 
assays of f/f and f/f;VEC BM cells were enumerated after 11 days in culture. n=12. 
Graphs show mean ± SEM. 
 
Figure 4.7. SLAM LSK percentage in f/f;VEC mice. The percentage of the SLAM 
LSK population enriched for long-term HSCs in f/f and f/f;VEC bone marrow, gated on 
the LSK population, followed by CD48
-
CD150
+
. Horizontal lines show mean ± SEM. 
 
Figure 4.8. f/f and f/f;VEC primary BMT peripheral blood assessment for donor 
chimerism. Primary transplantation of LSK cells from f/f and f/f;VEC donor mice. 
Peripheral blood of recipient mice assessed at 4, 8, and 12 weeks after primary 
transplantation for the percentage of donor-derived leukocytes (left panel). Donor 
contribution to myeloid, B-cell, and T-cell compartments in the peripheral blood at the 
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end of the primary transplants was analyzed by flow cytometry (right panel). Myeloid: 
Mac1
+
; B-cells: CD19
+
; T-cells: CD3
+
. Graphs show mean ± SEM. 
 
Figure 4.9. f/f and f/f;VEC primary BMT peripheral blood assessment for lineage 
distribution. Bars show lineage distributions within CD45.2 donor-derived cells of 
individual recipient mice (left Y-axis), while diamond symbols indicate total donor 
leukocyte percentages (right Y-axis) in the peripheral blood, at the end of the primary 
transplant. T: CD3
+
; B: CD19
+
; M: Mac1
+
. 
 
Figure 4.10. f/f and f/f;VEC secondary BMT peripheral blood assessment for donor 
chimerism. Secondary transplantation of total bone marrow from primary BMT 
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recipients. Peripheral blood of recipient mice assessed every 4 weeks after secondary 
transplantation for donor-derived leukocytes (left panel). Donor contribution to myeloid, 
B-cells, and T-cells in the peripheral blood at the end of the secondary transplants was 
analyzed by flow cytometry (right panel). Myeloid: Mac1
+
; B-cells: CD19
+
; T-cells: 
CD3
+
. Graphs show mean ± SEM. 
 
Figure 4.11. f/f and f/f;VEC secondary BMT peripheral blood assessment for lineage 
distribution. Bars show lineage distributions within CD45.2 donor-derived cells of 
individual recipient mice (left Y-axis), while diamond symbols indicate total donor 
leukocyte percentages (right Y-axis) in the peripheral blood, at the end of the secondary 
transplant. T: CD3
+
; B: CD19
+
; M: Mac1
+
. 
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Figure 4.12. Clonal analysis of f/;VEC bone marrow deletion efficiency. 
Representative PCR genotyping results of individual colonies from CFC assays of f/-
;VEC CKO mice. Controls are tail DNA isolated from f/f, f/- and f/-;VEC mice, showing 
the Arap3 floxed band (top band) and the Arap3 deleted band (bottom band). 
 
Figure 4.13. qRT-PCR analysis of f f/-;VEC bone marrow deletion efficiency. Arap3 
RNA transcript levels from BM of f/- and f/-;VEC mice were assayed by qRT-PCR and 
first normalized to Gapdh levels. The graph shows relative Arap3 transcripts remaining 
compared to that in f/f controls. Each symbol represents an individual mouse; horizontal 
lines indicate mean ± SEM levels. 
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Figure 4.14. Complete blood counts of  f/-;VEC mice peripheral blood. CBC of f/f 
(white bars), f/- (crosshatch bars), and f/-;VEC (gray bars) mice. n=5. Graphs show mean 
± SEM. 
 
Figure 4.15. Lineage distribution in f/-;VEC hematopoietic tissues. Percentage of 
various cell populations in the BM and spleen of f/f, f/-, and f/-;VEC mice was analyzed 
by flow cytometry, as defined by the surface markers indicated. n=5. Graphs show mean 
± SEM. 
 
Figure 4.16. CFC assays of f/-;VEC bone marrow cells. CFC assays of f/f, f/-, and f/-
;VEC BM cells were enumerated after 11 days in culture. n=5. Graphs show mean ± 
SEM. 
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Figure 4.17. Percentage of HSPC populations in f/-;VEC bone marrow. Percentage of 
various HSPC populations in the BM from f/f, f/-, and f/-;VEC mice was quantified using 
flow cytometry, defined by LSK and the SLAM markers CD48 and CD150. n=5. Graphs 
show mean ± SEM. 
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Figure 4.18. HSC frequency in f/-;VEC mice. HSC frequencies quantified using 
limiting dilution BMT assays of total bone marrow cells from f/- and f/-;VEC mice. 
Peripheral blood of recipient mice were analyzed 3-4 months after transplantation, with 
mice over 1% donor chimerism in every lineage of the blood (top panel) or over 1% in 
total donor-derived cells (bottom panel) counted as positive reconstitution. HSC 
frequencies: top panel: 1 in 42,188 (f/-), 1 in 72,928 (f/-;VEC); bottom panel: 1 in 21,215 
(f/-), 1 in 55,951 (f/-;VEC). Results pooled from 4 independent experiments. 
 
Figure 4.19. f/-;VEC primary BMT peripheral blood assessment for donor 
chimerism. Primary transplantation of LSK cells from f/f or f/- control and f/-;VEC CKO 
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donor mice. Peripheral blood in the recipients was assessed every 4 weeks post-primary 
transplant for the percentage of donor-derived cells. Data pooled from 4 independent 
experiments. n=18-24. Graphs show mean ± SEM. 
 
Figure 4.20. f/-;VEC primary BMT peripheral blood assessment for lineage 
distribution. Bars show average lineage distributions within donor-derived cells of all 
recipient mice at the end of the primary transplants. T: CD3
+
; B: CD19
+
; M: Mac1
+
. 
Graphs show mean ± SEM. 
 
Figure 4.21. f/-;VEC secondary BMT peripheral blood assessment for donor 
chimerism. Secondary transplantation of total bone marrow from primary BMT 
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recipients. Peripheral blood of recipients assessed at the end of the secondary transplant 
for the percentage of donor-derived cells by flow cytometry. Results pooled from 4 
independent experiments. n=18-24. Graphs show mean ± SEM. 
 
Figure 4.22. f/-;VEC secondary BMT peripheral blood assessment for lineage 
distribution. Bars show average lineage distributions within donor-derived cells of all 
recipient mice at the end of the secondary transplants. T: CD3
+
; B: CD19
+
; M: Mac1
+
. 
Graphs show mean ± SEM. 
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Figure 4.23. Donor chimerism post-reverse transplantation into VEC CKO mice. 
Reverse transplantation of wild-type CD45.1
+
 bone marrow cells into f/f and f/- control 
(SJL:CTL) or f/f;VEC and f/-;VEC CKO (SJL:VEC-CKO) mice were performed. Bars 
show average lineage distributions within CD45.1 donor-derived cells of all recipient 
mice at 8 weeks post-transplant. T: CD3
+
; B: CD19
+
; M: Mac1
+
. n=9 pooled from two 
independent experiments. Graphs show mean ± SEM. 
 
Figure 4.24. Donor-derived HSPCs in bone marrow after reverse transplantation 
into VEC CKO mice. Reverse transplantation of wild-type CD45.1
+
 bone marrow cells 
into f/f and f/- control (SJL:CTL) or f/f;VEC and f/-;VEC CKO (SJL:VEC-CKO) mice. 
Percentage of CD45.1
+
 LSK and SLAM LSK cells in the recipient bone marrow was 
quantified by flow cytometry 8 weeks post-transplantation. n=9 pooled from two 
independent experiments. Graphs show mean ± SEM. P-values determined by Student’s 
t-test. 
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Figure 4.25. Reconstitution after reverse secondary transplantation. 2000 CD45.1
+
 
donor LSK cells from primary reverse transplantation recipients were isolated and 
competitively transplanted into secondary wild-type recipients to look for functional 
reconstitution. Peripheral blood of secondary recipients was assessed every 4 weeks post-
transplantation. Dots show individual reconstituted mice; red circles indicate donor LSKs 
from f/f and f/- control primary recipients (SJL:CTL), and black squares indicate donor 
LSKs from f/f;VEC and f/-;VEC CKO primary recipients (SJL:VEC-CKO). Horizontal 
lines represent mean ± SEM. 
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Figure 4.26. Immunofluorescence imaging of E9.5 and E10.5 VEC CKO embryos for 
endothelial and hematopoietic cells. First full panel: E9.5 f/f;VEC, and f/-;VEC embryos 
show abnormal and delayed endothelial (CD31
+
) development compared to f/f controls. 
Hematopoietic clusters (Runx1
+
) should be localized to the AGM region as displayed in 
the f/f embryo, but show ectopic expression in the VEC CKO embryos. Second full panel: 
E10.5 f/f;VEC and f/-;VEC embryos display hematopoietic clusters in the major arteries 
in the expected proportions. The f/-;VEC embryo has a partially fused dorsal aorta, 
possibly accounting for the absence of Runx1
+
 cells in the fetal liver. Inset shows 
magnification of the dorsal aorta in f/f;VEC and f/-;VEC embryos compared with a non-
littermate wild-type E10.5 embryo. 
 
Figure 4.27. HSPC populations in f/-;Prx1 mice. Bone marrow cells from f/f control 
and f/-;Prx1 CKO mice were quantified for the percentage of cells in various HSPC 
populations using LSK and SLAM markers. n=3. Bars show mean ± SEM.  
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Figure 4.28. f/-;Prx1 BMT peripheral blood assessment for lineage distribution. 
Primary transplantation of LSK cells from f/f and f/-;Prx1 donor mice. Bars show lineage 
distributions within CD45.2 donor-derived cells of individual recipient mice (left Y-axis), 
while diamond symbols indicate total donor leukocyte percentages (right Y-axis) in the 
peripheral blood, at the end of the primary transplant. T: CD3
+
; B: CD19
+
; M: Mac1
+
. 
 
Figure 4.29. Donor chimerism post-reverse transplantation into Prx1 CKO mice. 
Reverse transplantation of wild-type CD45.1
+
 bone marrow cells into f/- control (SJL:f/-) 
or f/-;Prx1 (SJL:f/-;Prx1) mice were performed. Bars show average lineage distributions 
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within CD45.1 donor-derived cells of all recipient mice at 8 weeks post-transplant. T: 
CD3
+
; B: CD19
+
; M: Mac1
+
. n=6. Graphs show mean ± SEM. 
 
Figure 4.30. Donor-derived HSPCs in bone marrow after reverse transplantation 
into Prx1 CKO mice. Percentage of CD45.1
+
 LSK and SLAM LSK cells in the control 
(SJL:f/-) or CKO (SJL:f/-;Prx1) recipient bone marrow was quantified by flow cytometry 
8 weeks post-transplantation. n=6. Graphs show mean ± SEM. P-values determined by 
Student’s t-test. 
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Figure 5.1. Light microscope images of E11.5 KI embryos. KI/KI viable embryos at 
E11.5 appear more pale than WT or KI/+ heterozygous littermates, with slightly delayed 
development. Dead KI/KI embryos at E11.5 are shriveled and devoid of any vasculature 
or blood. 
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Figure 5.2. Erythroid development in E15.5 KI fetal livers. Fetal liver cells were 
analyzed by flow cytometry for the percentage of cells in various stages of erythroid 
differentiation, as fractionated by the surface markers CD71 and Ter119. Bars show 
percentage of cells in each erythroblast stage in individual E15.5 embryos. 
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Figure 5.3. Complete blood counts of KI/KI mice peripheral blood. CBC of f/f control 
mice (white bars) and KI/KI mutant mice (dotted black bars). n=4. Graphs show mean ± 
SEM. 
 
Figure 5.4. CFC assays of f/-;VEC bone marrow cells. Methylcellulose colony assays 
of f/f and KI/KI bone marrow cells were enumerated after 11 days in culture. n=3. Graphs 
show mean ± SEM. 
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Figure 5.5. SLAM LSK percentage in KI/KI mice. The percentage of the SLAM LSK 
population enriched for long-term HSCs in f/f and KI/KI bone marrow, gated on the LSK 
population, followed by CD48
-
CD150
+
. Horizontal lines show mean ± SEM. 
 
Figure 5.6. KI/KI primary BMT peripheral blood assessment for total donor 
chimerism. Primary transplantation of LSK cells from f/f and KI/KI donor mice. 
Peripheral blood of recipient mice assessed at 4, 8, and 12 weeks after primary 
transplantation for the percentage of donor-derived leukocytes. Results pooled from 2 
separate experiments, n=11-14. Graphs show mean ± SEM. P-values determined by two-
tailed Student’s t-test. 
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Figure 5.7. KI/KI primary BMT peripheral blood assessment for individual lineage 
donor chimerism. Donor contribution to myeloid, B-cell, and T-cell compartments in the 
peripheral blood at the end of the primary transplants was analyzed by flow cytometry. 
Myeloid: Mac1
+
; B-cells: CD19
+
; T-cells: CD3
+
. Graphs show mean ± SEM. P-values 
determined by two-tailed Student’s t-test. 
 
Figure 5.8. KI/KI primary BMT donor chimerism in the bone marrow. CD45.2
+
 
donor percentages in the total BM, LSK, and SLAM LSK compartments (CD48
-
CD150
+
LSK) of the bone marrow were enumerated by flow cytometry at the end of the 
primary transplants. Graphs show mean ± SEM. P-values determined by two-tailed 
Student’s t-test. 
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Figure 5.9. KI/KI primary BMT peripheral blood assessment for lineage 
distribution. Bars show lineage distributions within CD45.2
+
 donor-derived cells of 
individual recipient mice (left Y-axis), while diamond symbols indicate total donor 
leukocyte percentages (right Y-axis) in the peripheral blood, at the end of the primary 
transplants. T: CD3
+
; B: CD19
+
; M: Mac1
+
. 
 
Figure 5.10. KI/KI secondary BMT peripheral blood assessment for individual 
lineage donor chimerism. Secondary transplantation of total bone marrow from primary 
BMT recipients. CD45.2
+
 donor contribution to myeloid, B-cell, and T-cell 
compartments in the peripheral blood at the end of the secondary transplants was 
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analyzed by flow cytometry. Myeloid: Mac1
+
; B-cells: CD19
+
; T-cells: CD3
+
. Results 
pooled from 2 separate experiments, n=11-14. Graphs show mean ± SEM. P-values 
determined by two-tailed Student’s t-test. 
 
Figure 5.11. KI/KI secondary BMT donor chimerism in the bone marrow. CD45.2
+
 
donor percentages in the total BM, LSK, and SLAM LSK compartments (CD48
-
CD150
+
LSK) of the bone marrow were enumerated by flow cytometry at the end of the 
secondary transplants. Graphs show mean ± SEM. P-values determined by two-tailed 
Student’s t-test. 
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Figure 5.12. KI/KI secondary BMT peripheral blood assessment for lineage 
distribution. Bars show lineage distributions within CD45.2
+
 donor-derived cells of 
individual recipient mice (left Y-axis), while diamond symbols indicate total donor 
leukocyte percentages (right Y-axis) in the peripheral blood, at the end of the primary 
transplants. T: CD3
+
; B: CD19
+
; M: Mac1
+
. 
 
Figure 5.13. Reconstitution in KI/KI serial transplantations. Peripheral blood 
reconstitution in serial transplants was assayed by flow cytometry. 1°: primary; 2°: 
secondary; 3°: tertiary BMT. Results pooled from 2 separate experiments, n=11-14. 
Graphs show mean ± SEM. P-values determined by two-tailed Student’s t-test. 
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Figure 5.14. Donor chimerism post-reverse transplantation into KI/KI mice. Reverse 
transplantation of wild-type CD45.1
+
 bone marrow cells into control (SJL:CTL) or KI/KI 
(SJL:KI) mice were performed. Bars show average lineage distributions within CD45.1
+
 
donor-derived cells of all recipient mice at 8 weeks post-transplant. T: CD3
+
; B: CD19
+
; 
M: Mac1
+
. n=6-9 pooled from two independent experiments. Graphs show mean ± SEM. 
 
Figure 5.15. Donor-derived HSPCs in bone marrow after reverse transplantation 
into KI/KI mice. Reverse transplantation of wild-type CD45.1
+
 bone marrow cells into 
control (SJL:CTL) or KI/KI (SJL:KI) mice. Percentage of CD45.1
+
 LSK and SLAM LSK 
cells in the recipient bone marrow was quantified by flow cytometry 8 weeks post-
transplantation. n=6-9 pooled from two independent experiments. Graphs show mean ± 
SEM. P-values determined by Student’s t-test. 
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Figure 5.16. Reconstitution after reverse secondary transplantation. 3000 CD45.1
+
 
donor LSK cells from primary reverse transplantation recipients were isolated and 
competitively transplanted into secondary wild-type recipients to look for functional 
reconstitution. Peripheral blood of secondary recipients was assessed at 4 and 8 weeks 
post-transplantation. Dots show individual reconstituted mice; red circles indicate donor 
LSKs from control primary recipients (SJL:CTL), and black squares indicate donor LSKs 
from KI/KI primary recipients (SJL:KI). Horizontal lines represent mean ± SEM. 
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